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ABSTRACT
Background: Advanced-stage ovarian cancer survivors (OCS) often experience a multitude of
disease symptoms and treatment-related side-effects. Additionally, most OCS are older, have
comorbidities, are overweight or obese, and report being insufficiently physically active. Ovarian
cancer survivors may benefit from exercise oncology interventions to reduce symptom-burden,
manage comorbidities, minimize functional decline and maximize health-related quality of life
(HRQoL). However, current knowledge gaps regarding the physiological characteristics of OCS
throughout the entire survivorship spectrum challenge the development of tailored exercise
interventions.
Purpose: The overall purpose of this thesis was to provide a more comprehensive physiological and
activity behavior profile of post-treatment advanced-stage OCS. Specifically, a cross-sectional
research study was conducted to compare objectively measured activity behavior and physical
function, body composition and musculoskeletal morphology, self-reported pelvic floor dysfunction
(PFD) and HRQoL of OCS with age-matched controls. Associations between activity behavior,
physiological characteristics, PFD and HRQoL for OCS were also investigated.
Methods: Twenty stage III-IV OCS and 20 age-matched controls underwent objective assessments
of activity behavior (physical activity and sedentary time via 7-day accelerometry), physical
function (400-meter walk to assess cardiorespiratory fitness, repeated chair rise to assess lower
extremity function, 6-meter walking tests to assess gait speed and dynamic balance), muscle
strength (1-repetition maximum chest press and single leg extension, and handgrip strength), body
composition (dual-energy x-ray absorptiometry) and musculoskeletal morphology (peripheral
quantitative computed tomography), and completed questionnaires assessing HRQoL (SF-36) and
PFD (Australian Pelvic Floor Questionnaire).
Results: Compared to controls, OCS spent more time/day in prolonged sedentary bouts (i.e.,
uninterrupted sedentary bouts of ≥30 min; p = 0.039), had lower cardiorespiratory fitness (p =
ii

0.041) and upper body strength (p = 0.023), had higher areal bone mineral content (p = 0.047) and
volumetric trabecular density (p = 0.048), but were not different in other measures of body
composition or musculoskeletal morphology (i.e., all p-values > 0.050). Compared to controls, OCS
had equivalent self-reported PFD as indicated by combined bladder, bowel and pelvic organ
prolapse symptoms (p = 0.277), but worse physical HRQoL indicated by a physical composite score
(p = 0.013). Only 20% (n = 4) of OCS accrued ≥150 minutes/week moderate-and-vigorous physical
activity (MVPA) in ≥10 min bouts. MVPA time/day in ≥10 min bouts was positively associated
with cardiorespiratory fitness (p = 0.001), lower extremity function, (p = 0.019), muscle crosssectional area (p = 0.035), less PFD (p = 0.038) and physical HRQoL (p = 0.003). Decreased
physical HRQoL was associated with less MVPA (p = 0.005), more sedentary time (p = 0.047),
decreased objective physical function (p-values < 0.050) and greater PFD (p = 0.043).
Conclusion: Post-treatment advanced-stage OCS spent more time in prolonged sedentary bouts,
had lower cardiorespiratory fitness, upper body strength and physical HRQoL compared to agematched controls. The decreased physical HRQoL of this sample of OCS compared to controls and
its associations with modifiable factors such as MVPA, sedentary time, objective physical function
and PFD highlights the need for ongoing supportive care and the importance of multidisciplinary
interventions, including exercise oncology interventions, beyond the completion of first-line ovarian
cancer treatment.
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Chapter 1
INTRODUCTION
BACKGROUND
Ovarian cancer (OC) is the seventh most common cancer in women worldwide and the most
fatal gynecological cancer, with an estimated 255,660 new cases and 152,000 deaths in 2015.1 In
2018, an estimated 1613 women in Australia will be diagnosed with OC, and 1069 women will
succumb to the disease.2 Common risk factors associated with OC are older age, family history of
ovarian, breast and/or colorectal cancer, inherited mutations of BRCA1 and BRCA2 genes, use of
hormone replacement therapy, endometriosis and obesity.3, 4 Factors known to reduce the risk of
developing OC include oral contraceptive use, full-term pregnancy before age 26, multiple
pregnancies and gynecological surgery, i.e., hysterectomy and tubal ligation.3, 4
Ovarian cancers are often described as a group of heterogeneous diseases of uncertain
etiology, which can make diagnosis and treatment challenging.5-8 Unfortunately, the large majority
of OC cases (between 70% and 75%) are diagnosed at an advanced stage when the tumor has
already spread beyond the ovaries (stage III and IV).9 Two of the main reasons for this are the lack
of effective screening tests for OC coupled with diffuse early symptoms.10

Early signs and

symptoms of OC, most commonly abdominal and pelvic pain, bloating, difficulty eating or feeling
full quickly, and urinary frequency or urgency, are often vague and similar to symptoms of other
more common and often less serious health conditions.11 The five-year survival rates for women
with stage III and IV OC are 39% and 17%, respectively.12
Standard first-line treatment for advanced OC involves primary debulking surgery (PDS) to
remove as much of the tumor as possible, followed by adjuvant carboplatin-paclitaxel combination
1

chemotherapy.10 Optimal tumor debulking (i.e., removal of all visible tumor) is considered the most
important factor associated with prolonged OC survival.13,

14

Whether a tumor can be optimally

debulked depends on factors such as the patient’s age, co-morbidities, performance status, disease
stage, disease burden and location of metastatic sites.15 In cases where optimal debulking seems
unlikely, chemotherapy administered prior to debulking surgery, or neoadjuvant chemotherapy
(NACT), is an alternative treatment option increasingly being utilized worldwide.16 Although most
women respond well to first-line treatment, 70% of women with advanced-stage OC and up to 30%
of those with early-stage cancers will eventually relapse and require further treatment.17

18

Due to

the burden of advanced disease and often prolonged treatment, ovarian cancer survivors (OCS)
frequently experience persistent symptoms and side-effects such as fatigue, poor sleep quality,
peripheral neuropathy, cognitive impairment, sexual dysfunction and psychological distress.19-23
Many of these symptoms and side-effects have been associated with reduced quality of life.23, 24
Complicating the burden of advanced cancer and associated treatments, 50% of OCS are 63
years and older,25 75% have concurrent comorbidities26-28 and 15-30% are obese (i.e., BMI ≥30).26,
29-33

Furthermore, between 50% and 80% of OCS report being insufficiently physically active (i.e.,

engage in <150 minutes of moderate and vigorous physical activity per week).26, 27, 29, 34 Limited
research, most of which include mixed samples of gynaecological cancer survivors, suggest
impaired cardiorespiratory fitness and physical function in this cancer population.34-36 Ovarian
cancer survivors may benefit from supportive care interventions to reduce symptom-burden,
manage comorbidities, minimize functional decline and maximize health-related quality of life.
Considerable research has demonstrated multiple benefits of physical activity and exercise
after a cancer diagnosis.35,

37-39

Physical activity is commonly defined as “any bodily movement

produced by skeletal muscles that results in energy expenditure” and includes occupational,
household and sport activities, and exercise. Exercise is a subset of physical activity and refers to
planned, structured and repetitive activity with the purpose to improve or maintain physical fitness
and health.40 However, the majority of this evidence, as well as current physical activity (PA) and
2

exercise oncology guidelines endorsed by professional organizations such as the American College
of Sports Medicine and American Cancer Society, are primarily based on research over the past two
decades involving breast and prostate cancer survivors.37 Research evidence for the benefits of PA
and exercise in OC is limited to small, non-randomized studies.41-43 To inform the design of OCspecific exercise oncology interventions for both research and clinical settings, a more
comprehensive activity behavior and physiological profile of OCS is needed. A challenge posed by
most existing OC research is the notable lack of objectively measured data describing body
composition, activity behaviors (i.e., PA and sedentary behavior) and physical function.
Furthermore, information on pelvic floor dysfunction (PFD), a recognized barrier to physical
activity and exercise44,

45

and associated with reduced health-related quality of life (HRQoL) in

women globally,46, 47 is limited to studies with mixed samples of gynecological cancer survivors. 48,
49

Also, most current OC studies include heterogeneous samples of participants including women

with different stages of cancer, often on different treatments and at different time points in the
cancer trajectory. Particularly lacking is information regarding the post first-line treatment status of
advanced OCS.

RESEARCH SIGNIFICANCE
The need for tailored supportive care interventions such as exercise prescription to reduce
the impact of OC and its treatment is often highlighted in research studies.24, 26, 33, 41, 50-52 However,
a comprehensive picture of objective activity behaviors and physical function, muscle strength,
body composition, musculoskeletal morphology and pelvic floor symptoms in OCS is not available.
This presents a challenge for the design of tailored exercise intervention studies and exercise
oncology guidelines. Results from this study will provide a more comprehensive activity behavior
and physiological profile of advanced-stage OCS to empirically inform the design and application
of OC-specific exercise oncology interventions for both research and clinical practice.

3

RESEARCH PURPOSE AND OVERVIEW
The purpose of this research is to provide a comprehensive activity behavior and
physiological profile of post-treatment advanced-stage OCS. Chapter Two is a published narrative
review of existing literature relating to the physiological characteristics of OCS in terms of
treatment-related side-effects, concurrent comorbidities, body weight and composition, physical
fitness and function, and self-reported physical activity behavior.53 In Chapters Three and Four we
present results of an original cross-sectional research study conducted with 20 advanced-stage OCS
who had received either neoadjuvant chemotherapy treatment and interval debulking surgery, or
primary debulking surgery and adjuvant chemotherapy treatment. More specifically, in Chapter
Three we describe objectively measured activity behaviors (PA and sedentary behavior) and
physiological characteristics (physical function, muscle strength, body composition and
musculoskeletal morphology) of OCS compared to age-matched controls (Manuscript under review,
International Journal of Gynecological Cancer, Manuscript No. IGC-D-17-00571). In Chapter Four
we compare HRQoL and self-reported PFD of OCS with age-matched controls and examine
correlations between HRQoL and PFD (Manuscript prepared for submission to Supportive Care in
Cancer, October 2017). Finally, in Chapter Five we provide an overall critical discussion of major
findings and conclusions of our narrative review and experimental chapters, with recommendations
for future research.
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Chapter 2
LITERATURE REVIEW

“A physiological profile of ovarian cancer survivors to inform tailored exercise
interventions and the development of exercise oncology guidelines”

Schofield C, Newton RU, Galvão DA, Cohen PA, Peddle-McIntyre CJ. International Journal of
Gynecological Cancer. 2017;27:1560-1567.
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ABSTRACT
Objective: Physical activity has become increasingly important in supportive cancer care.
However, physical activity and exercise guidelines for ovarian cancer survivors remain generic. The
aim of this narrative review is to summarize existing data regarding the physiological characteristics
(treatment-related adverse effects, concurrent comorbidities, body weight and composition, physical
fitness and function, and physical activity behavior) of ovarian cancer survivors to further
understanding of their cancer-specific physical activity and exercise needs. We also highlight gaps
in the current knowledge base.
Methods: We undertook a narrative review of current literature on the physiological status of
ovarian cancer survivors. We defined physiological status as treatment-related adverse effects,
concurrent comorbidities, body weight and composition, physical fitness and function, and physical
activity behavior.
Results: In addition to disease- and treatment-related symptoms and adverse effects, the majority of
ovarian cancer survivors have comorbidities, which may adversely affect treatment effectiveness
and safety, as well as survival. Despite high overweight and obesity rates, a large percentage of
women are malnourished at diagnosis, with potentially compromised muscle mass and muscle
density. Low muscle density at diagnosis and loss of muscle mass during treatment may be
associated with worse survival outcomes. A small number of studies have observed impaired
physical function and cardiorespiratory fitness in ovarian cancer survivors. The majority of ovarian
cancer survivors are insufficiently active or sedentary.
Conclusion: Our review suggests that ovarian cancer survivors could benefit from physical activity
and exercise oncology interventions aimed at addressing detrimental changes to physiological status
due to disease and treatment. However, current knowledge gaps regarding the physiological
characteristics of ovarian cancer survivors throughout the entire survivorship spectrum challenges
the development of tailored exercise intervention studies and exercise oncology guidelines.
Key Words: Ovarian cancer, Comorbidities, Body composition, Physical fitness, Physical activity
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INTRODUCTION
Ovarian cancer (OC) is the seventh most common cancer in women worldwide and the
most lethal gynecological malignancy, with an estimated 255,660 new cases and 163,765 deaths in
2015.1 Due to lack of effective screening tests and the non-specific nature of symptoms, 70-75% of
women with OC receive the diagnosis at an advanced stage (stages III-IV).2 Standard treatment for
OC involves either primary surgery followed by adjuvant paclitaxel-carboplatin combination
chemotherapy, or neoadjuvant chemotherapy with interval debulking surgery.3 Although most
women initially respond well to treatment, recurrence rates are high, with 70% of advanced-stage
OCs and up to 30% of early-stage OCs eventually relapsing and requiring further treatment.4, 5 The
aim of treatment after recurrence is to control the disease and disease-related symptoms, limit
treatment toxicities and prolong time to disease progression and death, whilst optimizing quality of
life.2 Identifying appropriate, targeted adjuvant interventions to reduce symptom-burden and
minimize functional decline and disability are crucial in the ongoing care of OC survivors.
Physical activity is defined as “any bodily movement produced by skeletal muscles that
results in energy expenditure.” Exercise as a subset of physical activity refers to planned, structured
and repetitive activity with the purpose to improve or maintain physical fitness and health.6 Physical
activity is important in the management of many chronic conditions and the prescription of exercise
as “medicine” should be integral in the treatment of chronic diseases such as cancer.7 The term
“cancer survivor” is based on the National Comprehensive Cancer Network definition and refers to
people living with cancer, from the time of diagnosis, through all disease stages, until death.8
Higher physical activity levels in cancer survivors have been associated with reduced disease and
treatment adverse effects, increased physical and emotional well-being,9 as well as reduced risk of
recurrence, cancer-specific and all-cause mortality in certain cancer groups.10, 11 Since the American
College of Sports Medicine published initial guidelines and recommendations for exercise
oncology12 other professional and cancer organizations (e.g. American Cancer Society, National
Comprehensive Cancer Network) have endorsed the concept that cancer survivors should avoid
12

physical inactivity and, if possible, undertake 150 minutes of aerobic exercise a week and twiceweekly resistance exercises (REs).13 However, most of these recommendations have been based on
research over the past 2 decades involving primarily breast and prostate cancer survivors. As a
result, there is a logical and clinical requirement to understand and identify gaps in knowledge,
particularly for understudied cancers such as OC.14 Research to help tailor physical activity
guidelines and exercise interventions to specific cancer groups is crucial to maximize the impact of
physical activity and exercise interventions in clinical and research settings and to further advance
the field of exercise oncology.
The purpose of this review is to synthesize published literature on treatment-related adverse
effects, concurrent comorbidities, body weight and composition, physical function and fitness, and
physical activity behavior of OC survivors to provide a more complete physiological profile of this
cancer group. A secondary aim is to highlight key gaps in knowledge to inform future research.
Improved knowledge of the multifaceted challenges faced by OC survivors will support the
development of exercise oncology recommendations specifically for OC survivors. In addition, it
will provide a scientific basis for the design and application of tailored exercise interventions in
both research and clinical settings (Fig 1).

METHODS
Information for this review was obtained by searching the PubMed, Medline, CINAHL and
SPORTDiscus databases for relevant articles in English published between January 1970 and
December 2016 pertaining to treatment-related adverse effects, comorbid conditions, body weight,
body composition, physical function and fitness, and exercise and physical activity levels in OC
survivors. Search terms included “OC,” “ovarian neoplasms,” “treatment” (side-effects, symptoms),
“comorbidities,” “BMI,” “body composition,” “physical fitness” (muscular strength, muscular
endurance, cardiorespiratory fitness, cardiovascular fitness), “physical function” (grip strength, gait
speed, walking speed, mobility, balance), and “physical activity” (physical activity behavior, habits,
participation, levels, exercise). Reference lists of relevant papers were also searched. Review
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articles, randomized controlled trials, cross-sectional studies and observational cohort studies
published in peer-reviewed journals as full-text articles were reviewed by CS. Abstracts, case
reports, editorials and study protocols were excluded.

RESULTS
Treatment-related Adverse Effects
The cumulative adverse effects of surgery, chemotherapy, and targeted therapy can have a
debilitating impact on the lives of OC survivors, both during and following treatment.15
Acute adverse effects commonly reported during OC treatment include fatigue, pain,
appetite loss, constipation, diarrhea, nausea, vomiting and dyspnea. Abdominal discomfort (pain,
bloating, cramping and indigestion), insomnia, neuropathy, sexual dysfunction, weight gain, and
weight loss are also common.16 Women with advanced stage or recurrent OC who are treated with
bevacizumab in addition to chemotherapy can experience hypertension, proteinuria, wound-healing
complications, thrombotic events, and gastrointestinal perforation.17, 18
Chronic adverse effects continue to affect at least 20% of disease-free OC survivors
regardless of stage of disease.19-21 Fatigue is the most prevalent physical burden for women with
active disease.22 Poor sleep quality, chemotherapy-related cognitive impairment and peripheral
neuropathy affect 60% to 70% of survivors of stages I to IV OC at least 1 year after diagnosis.23-25
Gastrointestinal issues such as constipation, diarrhea, indigestion and flatulence remain burdensome
in 16% to 47% of OC survivors years after treatment completion.24, 25 The majority of survivors
report no sexual activity 3 years or more after treatment completion,26, 27 and more than 70% of
women who remain sexually active experience sexual discomfort.26 Although sexual and
gastrointestinal dysfunction in this group of cancer survivors is well documented, data regarding the
prevalence, severity and impact of pelvic floor dysfunction are limited. Such data are crucial for the
design of OC-specific exercise interventions.
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About 20% of all OC survivors will experience anxiety and depression at some point in their
cancer trajectory.28 Fear of recurrence is a major cause of psychological distress for survivors of all
ages, irrespective of disease stage or treatment received.29 Depressive symptoms are strongly
correlated to physical symptoms, fatigue, poor sleep quality, physical function and quality of life.23,
30, 31

More research is needed to determine if, and how, these physical and psychological symptoms

and adverse effects change over time and whether differences are treatment related (eg, neoadjuvant
vs adjuvant chemotherapy).

Concurrent Comorbidities
Cancer survivors are more likely to have multiple chronic medical conditions than agematched

control

subjects.32

Although

prevalence

rates

vary,

hypertension,

arthritis,

hypercholesterolemia, thyroid disorders and musculoskeletal issues are commonly reported in OC
survivors.20-22, 24, 33-35 Approximately 75% of OC survivors self-reported 1 or more comorbidities in
separate cross-sectional survey studies.21, 34, 36 By contrast, 1 or more comorbidities were identified
in only 25% of survivors when information from cancer registries was used.37 This discordance may
be due to response bias and/or ascertainment bias, which are inherent in such studies. The
prevalence of comorbidities does not appear to differ significantly between survivors of early- and
advanced-stage OC,38 although obese survivors are more likely to have comorbidities.39 Research
suggests that women with comorbidities are less likely to receive standard cytoreductive surgery
and/or combination chemotherapy,40 and have poorer survival outcomes.41 Thus, knowledge about
the status and severity of concurrent comorbidities throughout the survivorship spectrum, as well as
a better understanding of the impact of concurrent medications on OC treatment and treatment
toxicity, is crucial, especially in light of the confirmed benefit of exercise to manage chronic
conditions.7
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Body Weight
Obesity (as indicated by a body mass index [BMI] of ≥30 kg/m²) is associated with a higher
risk of recurrence and mortality in many cancer groups.42 Obesity rates in OC range between 15%
and 30%,36,

43-47

however, findings on the impact of obesity on OC prognosis have been

inconsistent. A systematic review and meta-analysis by Bae et al48 found no association between
BMI at time of diagnosis and survival. In contrast, a recent meta-analysis, which included 12,390
OC survivors from 21 studies, concluded that obesity at or before diagnosis negatively affects
survival in low-grade serous, endometrioid and high-grade serous OCs, but not in clear-cell or
mucinous cancers.49 This may reflect the heterogeneity of studies in these meta-analyses. While the
impact of obesity on survival after an OC diagnosis has not been fully elucidated,48, 50 increased
BMI may adversely affect treatment effectiveness and safety. Obese women are more likely to
experience

suboptimal

chemotherapy dosing,

postsurgical

complications50

and

hospital

readmissions.51 Complications that delay or disrupt adjuvant chemotherapy treatment may have a
negative impact on quality of life, and potentially survival.50 The adverse effects of obesity on
treatment outcomes and possibly survival warrants further investigation. For example, studies
investigating the impact of increased physical activity or participation in structured and regular
exercise interventions on BMI after an OC diagnosis are needed.
While several studies have addressed the impact of obesity on OC outcomes, information
about the prevalence and impact of weight loss during the disease trajectory, and underweight status
(as indicated by a BMI <18.5 kg/m²) is limited. Data suggest that 40% to 60% of women with
advanced-stage OC lose weight during adjuvant chemotherapy.45,

52

However, the relationship

between weight loss during treatment and changes in body composition has yet to be elucidated. In
addition, how weight loss impacts treatment and whether weight loss continues after completion of
treatment remains unclear. Low rates of underweight women (2%-9%) have been reported across all
disease stages,53-56 and conclusions regarding the impact of underweight status on survival are
conflicting. Separate studies associate BMI of less than 18.5 kg/m² at diagnosis in all disease
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stages,55 and after treatment completion in advanced stage,53 with increased mortality. Conversely, a
recent meta-analysis found no association between underweight status and disease stage or survival,
but concluded that more data are needed to confirm this finding.56 More research is needed to
delineate the impact of overweight or underweight status, as well as weight change in all disease
stages throughout the survivorship spectrum.
The relationship between OC survivors’ body weight and nutritional status is complex.
While less than 10% of women are underweight,56 30% to 67% are malnourished at diagnosis,
based on nutrition assessment tools such as the Patient-Generated Subjective Global Assessment
and the Nutritional Risk Index.44, 52, 57, 58 The presence of ascites and a high body fat percentage at
any time point will “inflate” BMI values and mask muscle wasting, a consequence of
malnourishment.59 In addition to BMI, body composition measures can provide much needed
objective data to identify OC survivors with low muscle mass and/or excess body fat in need of
dietary and exercise interventions.

Body Composition
Low muscle mass may be associated with increased treatment toxicity and mortality in
cancer survivors.60 To date only a small number of studies have examined body composition and
muscle quality in OC survivors. Low muscle mass, indicated by a skeletal muscle index below 39.0
cm²/m², was observed in 45% of a large cohort of women with newly diagnosed advanced-stage
OC.61 The skeletal muscle index was calculated by dividing skeletal muscle area (in centimeters
squared), measured preoperatively with computed tomography at the level of the third lumbar
vertebra, by the height squared (in meters squared). However, current data do not confirm an
association between low muscle mass at diagnosis and OC survival.46, 59, 61 An important finding by
Rutten et al.59 is the association of skeletal muscle loss during neoadjuvant chemotherapy with
decreased survival, although this finding requires further confirmation.

17

Recent evidence suggests that muscle density, more so than muscle mass, could be an
important prognostic factor in OC. Preliminary evidence indicates a positive association between
skeletal muscle attenuation (a measure of muscle density, with lower values indicating a higher
muscle fat content) and survival in certain cancer groups.62 Low skeletal muscle attenuation at
diagnosis was associated with decreased overall survival in 2 separate OC studies.46, 61 The findings
of these retrospective studies require validation in future randomized controlled trials.
In addition to potential changes in muscle and fat content, OC survivors may experience
alterations in bone mineral density. However, the prevalence of osteopenia and osteoporosis are
seldom reported in OC studies. Although bone loss has been observed in pre- and postmenopausal
OC survivors in the first year after diagnosis,63-65 these studies included gynecological cancer
survivors with only small samples of OC survivors (n = 30, 15 and 12, respectively). Given that
bone-related comorbidities (eg, osteoporosis) could have a significant impact on exercise
prescription, more research is needed to understand the prevalence of, and changes in, bone mineral
density throughout the OC trajectory.

Physical Fitness and Function
Physical fitness is historically defined as “the ability to carry out daily tasks with vigor and
alertness, without undue fatigue.” The term encompasses several measurable components, including
cardiorespiratory capacity and endurance, muscular strength and endurance, body composition, and
flexibility,6 all of which potentially affect physical function in cancer survivors.66 Information
regarding OC survivors’ cardiorespiratory and muscular fitness is lacking, with only a limited
number of nonrandomized exercise intervention studies reporting these measures.67, 68 Data from a
small cross-sectional study suggest impaired cardiorespiratory fitness in gynecological cancer
survivors many years after diagnosis, when compared with age-matched control subjects.69 This
finding is important considering the strong inverse association between cardiorespiratory fitness and
cancer mortality, independent of adiposity level.70
18

Impairments in physical function predict disability, institutionalization and mortality in
older people71 and may predict mortality in cancer survivors.72 Research regarding physical
function in OC survivors is limited and mostly measures self-reported physical function with
quality-of-life instruments. Only 10% of a small sample of long-term survivors of stages III to IV
OC without evidence of recurrent disease reported functional limitations.19 In contrast, impaired
physical function was reported by 38% of more than 5000 gynecological cancer survivors, which
included 922 OC survivors, at least one year since diagnosis. Participants were considered
functionally impaired if they responded “yes” to 1 or both questions regarding limitations in
activities and use of special equipment due to health problems.73 Self-rated functional impairment in
OC survivors is associated with lower physical activity levels,36,

73

older age,15 obesity,36

comorbidities, fatigue,74 peripheral neuropathy,35 and increased psychological distress.75 Physical
function has seldom been objectively measured in OC research. One study found an association
between physical function, measured objectively using the Short Physical Performance Battery and
usual gait speed, and mortality in a mixed sample of older gynecological cancer survivors,76
indicating a need for more quantitative data regarding physical function in OC survivors.
Considering evidence from other cancer groups such as breast and prostate cancer,12
exercise interventions are likely to be an effective strategy to improve physical fitness and function
in OC survivors. However, such strategies need to be tested in OC survivors in adequately powered
prospective, controlled clinical trials.

Physical Activity Participation
Ovarian cancer survivors’ physical activity participation rates are low. In comparison to
27% of women and 35% of women in high-income countries, worldwide,77 50% to 80 % of OC
survivors reported insufficient physical activity levels (ie, <150 minutes of moderate and vigorous
physical activity per week) or a sedentary lifestyle (ie, no moderate and vigorous physical activity
per week) after treatment completion.34,

36, 43, 73

Research suggests that most women decrease
19

physical activity levels after diagnosis,78 and many do not return to pre-diagnosis levels.79
Interestingly, OC survivors’ participation rates in RE (ie, exercise that involves performing sets of
repeated movements against a resistance, such as lifting weights)80 have not been previously
reported. However, considering research in other cancer survivor populations, where participation
in sufficient RE (ie, ≥ 2 sessions/wk for ≥ 30 minutes) is only 10%,81 participation is likely to be
low. Information regarding OC survivors’ participation rates in RE and the feasibility of RE
programs is important, especially considering the positive effects of RE on muscular strength and
body composition in cancer survivors.82
Higher levels of physical activity after a cancer diagnosis are associated with a reduced risk
of cancer-specific and all-cause mortality in breast, colorectal and prostate cancer.10,

11

The

association between physical activity after an OC diagnosis and mortality remains unclear, although
prediagnostic physical activity appears to affect survival in this cancer group.83 Ovarian cancer
survivors who report being more physically active have reduced symptom burden, improved
physical fitness and function, and a better quality of life.34,

36, 67, 68, 84

However, most studies

investigating physical activity in OC survivors are cross-sectional in design, which precludes
inferring conclusions about causality and indicates a need for future prospective randomized
controlled trials. In addition, limitations of self-reported physical activity, such as overreporting,85
must be considered when interpreting the results of these studies. Objective assessment of physical
activity should be included in future studies to provide more comprehensive, valid, and reliable data
about physical activity participation and patterns of sedentary behavior.
Ovarian cancer survivors often express interest in participating in physical activity
programs,86,

87

but frequently report a combination of demographic, medical and motivational

barriers to physical activity and exercise participation.78 Demographic and medical barriers include
older age, higher BMI, shorter time since diagnosis, or current disease.88 The most commonly
reported barriers to exercise are fatigue (37.8%), exercise not being part of usual routine (34.7%),
and lack of self-discipline (32.6%).78
20

SUMMARY AND AREAS FOR FUTURE RESEARCH
Women with a diagnosis of OC often experience a range of physical and psychological
symptoms and adverse effects during and after cancer treatment, regardless of disease stage. In
addition, about 75% of women have self-reported comorbidities,21,

34, 36

and 15% to 30% are

obese,36, 43-47 both of which may adversely affect treatment and survival. Despite high overweight
and obesity rates, a large percentage of women are malnourished at diagnosis, with potentially
compromised muscle mass and muscle density. This is particularly important in OC survivors
because low muscle density at diagnosis and loss of muscle mass during treatment may be
associated with worse survival outcomes. A small number of studies have observed impaired
physical function and cardiorespiratory fitness in OC survivors. Despite high levels of interest in
physical activity programs, and some evidence for an association between physical activity and
physical well-being, 50% to 80% of OC survivors are insufficiently active or sedentary because of
numerous demographic, medical and behavioral barriers.34,

36, 43, 73

Because of a current lack of

scientific knowledge, physical activity and prescription of regular and structured exercise might not
be optimally promoted by the OC care team.
The greatest challenge for the design and application of evidence-based exercise oncology
guidelines in OC care is the heterogeneity of existing studies. To date, most studies have included
women with all stages and grades of cancer, often on different treatment regimens and at different
time points in the cancer trajectory. Furthermore, the majority of studies reporting on comorbidities,
body weight and body composition, physical fitness and function, and physical activity habits are
cross-sectional or retrospective in nature, and do not provide information on changes in
physiological status of OC survivors over the course of the cancer trajectory. A further challenge is
the notable lack of objectively measured data describing physical activity behavior, physical fitness
and physical function.
Future research should aim to provide evidence-based objective information describing the
physiological characteristics of OC survivors throughout the entire survivorship spectrum, with
21

careful consideration of potential differences due to disease stage, treatment regime or survivorship
stage. Such information will provide a better understanding of the impact of OC and its treatment
and will empirically inform the design and application of OC-specific exercise oncology guidelines,
thus maximizing the potential impact of exercise medicine in both clinical and research settings.
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Treatment-related side-effects
-Fatigue, peripheral neuropathy, poor sleep
quality, cognitive and sexual dysfunction common
-Can persist after treatment completion

Reduced symptom burden
associated with higher physical
activity rates*

Comorbidities
-High rates
-hypertension, arthritis, hypercholesterolemia,
thyroid disorders and musculoskeletal issues

Sub-optimal treatment*
Decreased physical function*
Decreased survival*

Body weight
-High overweight and obesity rates

Sub-optimal treatment*
Decreased physical function*
Decreased survival*

Exercise interventions with appropriately
prescribed resistance and cardiorespiratory
exercise could assist to:
- Reduce treatment-related side-effects
- Better manage comorbidities
- Positively alter body composition by:
-Reducing fat mass
-Increasing muscle mass and density
- Increase muscle strength and endurance

Body composition
-Decreased muscle mass and muscle density*

Decreased survival*

- Increase physical function
- Reduce symptom burden

Physical fitness and function
-Decreased cardiorespiratory fitness*
-Decreased physical function*

Physical activity participation
-Low rates
-High interest in physical activity programs, but
unmet needs

- Increase cardiorespiratory fitness

No evidence

- Increase physical activity levels
- Increase quality of life

-

Low physical activity rates
associated with:
Increased symptom burden*
Decreased physical fitness*
Decreased physical function*
Decreased quality of life*

Figure 1. Opportunities for exercise oncology interventions in OC care based on current evidence
(* limited data) Physical activity refers to minutes of moderate and vigorous exercise/week.
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Chapter 3
OBSERVATIONAL STUDY

“Activity behaviors and physiological characteristics of women with advanced-stage
ovarian cancer: a comprehensive cross-sectional investigation”

Schofield C, Newton RU, Galvão DA, Cohen PA, McVeigh JA, Hart NH, Mohan GR, Tan J,
Salfinger SG, Straker LM, Peddle-McIntyre CJ. International Journal of Gynecological Cancer.
Under review.
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ABSTRACT
Objectives: Ovarian cancer survivors (OCS) experience many disease and treatment adverse
effects. Yet, the impact of ovarian cancer and its treatment on objective activity behaviors and
physiological status has not been comprehensively examined. The purpose of this study was to
compare objectively measured activity behaviors and physiological characteristics of advancedstage OCS to age-matched controls. Secondarily, OCS who underwent different treatment regimens
were compared.
Methods: Twenty stage III-IV OCS and 20 controls completed assessments of activity behaviors
(7-day accelerometry), physical function (400-meter walk as indicator of cardiorespiratory fitness,
repeated chair rise, 6-meter walking tests), muscle strength (1-repetition maximum and hand grip),
body composition (dual-energy x-ray absorptiometry) and musculoskeletal morphology (peripheral
quantitative computed tomography).
Results: Compared to controls, OCS spent more time/day in prolonged sedentary bouts (p = 0.039),
had lower cardiorespiratory fitness (p = 0.041) and upper body strength (p = 0.023), had higher
areal bone mineral content (p = 0.047) and volumetric trabecular density (p = 0.048), but were not
different in other measures of body composition, nor in muscle morphology (p-values > 0.050).
Appendicular lean mass was significantly higher for women who received neoadjuvant
chemotherapy compared to those who received adjuvant chemotherapy (p = 0.045). Only 20% (n =
4) of OCS accrued ≥150 minutes/week moderate-and-vigorous physical activity (MVPA) time in
≥10 min bouts. MVPA time/day in ≥10 min bouts was associated with cardiorespiratory fitness (p =
0.001), lower extremity function (p = 0.019) and muscle cross-sectional area (p = 0.035).
Conclusion: Post-treatment OCS spent more time in prolonged sedentary bouts and had lower
cardiorespiratory fitness and upper body strength compared to controls. MVPA was associated with
physical function and muscle cross-sectional area. Future studies should test the efficacy of exercise
interventions to increase MVPA, reduce sedentary behavior, and increase cardiorespiratory fitness
and muscle strength in OCS.
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INTRODUCTION
Ovarian cancer (OC) is the most lethal gynecological malignancy with an estimated 255,660
new cases and 163,765 deaths worldwide in 2015.1 Most cases are diagnosed at an advanced stage.2
Standard first-line treatment for OC involves primary debulking surgery (PDS) followed by
adjuvant carboplatin-paclitaxel combination chemotherapy. Neoadjuvant chemotherapy (NACT)
with interval debulking surgery is an alternative treatment for women with stage IV disease,
unresectable bulky tumors and poor performance status.3 Approximately 70% of women diagnosed
with advanced OC will relapse and require additional treatment.4
Beyond the burden of OC, most ovarian cancer survivors (OCS) have comorbidities5, 6 and
are overweight or obese.6-8 Between 50% and 80% report insufficient participation in physical
activity (PA),5, 6, 8, 9 with initial reports suggesting impaired physical function in this population.9, 10
However, most studies to date have assessed PA and physiological characteristics with self-report
measures in heterogeneous groups of OCS involving women with diverse stages of disease and
treatment regimens across varied time-points in the disease trajectory.11 As a result, consequences
of OC and its treatment on objectively measured activity behaviors (PA and sedentary behavior
[SB]), physical function, body composition, and muscle morphology (cross-sectional area [CSA]
and density) remain largely undefined.
Due to a paucity of information on objectively measured activity behaviors in OC research,
the relationship of objectively measured PA and sedentary behavior with physical function and
body composition in this cancer population is also poorly understood. Existing research indicates a
positive association between objectively measured moderate and vigorous PA (MVPA) and
physical function in colon cancer survivors,12 while objective measures of MVPA is inversely
associated with waist circumference in prostate cancer survivors.13 Objectively measured sedentary
time has been inversely associated with physical function in long-term cancer survivors14 and
performance status and survival in patients with malignant pleural effusion.15 Considering the
discrepancy between self-reported and objectively measured PA and sedentary time,16,
34
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quantification of OCS’ activity behaviors and physiological characteristics, and of the association
between them, is critical for development and testing of targeted interventions aimed at improving
patient outcomes.
In this cross-sectional study we compared objectively measured activity behaviors and a
range of objective physiological measures in a cohort of women with advanced-stage epithelial OC
following first-line treatment to age-matched controls. We also examined potential differences in
advanced-stage OCS treated by NACT and interval debulking surgery compared to women treated
by PDS and adjuvant chemotherapy. Lastly, we explored associations of objectively measured
activity behaviors with objective measures of physical function, body composition and muscle
morphology in OCS.

METHODS
Setting and Participants
The study was conducted at the Exercise Medicine Research Institute at Edith Cowan
University and St John of God Subiaco Hospital in Perth, Western Australia. Ethical approval was
granted by the Edith Cowan University (Ref. No. 12511, 23/4/2015) and St John of God Health
Care Human Research Ethics Committees (Ref. No. 815, 12/6/2015). Eligibility criteria were:
histologically confirmed stage III–IV epithelial OC, 3-24 months post completion of treatment, ≥18
years of age, approval from the treating oncologist or general practitioner, able to walk 400 meters,
proficient in English, no existing or suspected bone metastases, no acute illness or any
musculoskeletal, cardiovascular or neurological disorder that could put the participant at risk during
exercise testing. The same non-cancer eligibility criteria applied for the control group. Written
informed consent was obtained from all participants.
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Recruitment
Eligible patients were identified via consulting rooms of three gynecologic oncologists and
were informed of the study by phone or letter. The principle investigator (CS) phoned patients to
confirm interest and eligibility. Control group participants were recruited via snowball sampling,
from staff at a local university and hospital, and from the wider community. A study information
pack was posted to all eligible participants.
Ovarian cancer group:

Non-cancer control group:

86 post-treatment stage IIIIV ovarian cancer survivors
identified

35 female volunteers with no
previous cancer diagnosis
identified

Reasons for ineligibility (n=42)
Uncontactable (n=17)
Recurrent disease (n=12)
Medical contraindications (n=5)
Deceased (n=4)
On treatment (n=4)

44 stage III-IV ovarian cancer
survivors eligible

Reasons for ineligibility (n=4)
Outside identified age range (n=4)

31 women with no previous
cancer diagnosis eligible

Reasons for non-enrolment (n=24)
Not interested (n=12)
Lives too far (n=6)
“Too old” (n=2)
Family or work commitments (n=3)
Travelling (n=1)

20 ovarian cancer survivors
enrolled

Reasons for non-enrolment (n=11)
Unable to age match to
experimental participant (n=8)
Withdrew interest (n=3)

20 women with no previous
cancer diagnosis enrolled

Figure 2. Participant recruitment flowchart
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Outcome Measures
Demographic and medical data regarding participants’ age, marital status, education level,
employment status and medical history were obtained by self-report questionnaire. Additional
information regarding cancer diagnosis and treatment were collected from OCS. All
anthropometric, body composition and objective functional data were collected at the Exercise
Medicine Research Institute by one investigator (CS). Participants attended two sessions (i.e., a
familiarization session followed by a testing session) no less than six, but no more than 14 days
apart.

Anthropometric Measures
Height and body weight, measured by a digital measuring-and-weighing station (Model 763,
Seca, Hamburg, Germany), were used to calculate body mass index (BMI; kg/m²). Waist and hip
circumference were measured at the narrowest part of the torso or between the iliac crest and 12th
rib, and the maximal circumference of the hip.18 Waist-to-hip ratio was calculated by dividing waist
circumference by hip circumference.

Physical Activity and Sedentary Behavior
Objective PA and sedentary time were measured with a hip-worn tri-axial accelerometer
(ActiGraph GT3X+, ActiGraph Corp, FL, USA). Participants were asked to wear the accelerometer
continuously for seven days, except when bathing/showering or participating in water-based
activities. The GT3X+ was programmed to record raw data at a frequency of 30Hz, which were
later reduced to vertical axis movement counts/60 s epoch
for the purpose of our analyses. Accelerometer data were downloaded with Actilife (Version 6.13.3,
ActiGraph Corp, FL, USA) and processed in SAS (Version 9.3, SAS Institute Inc., NC, USA). An
automated algorithm was used to identify awake wear time.19 To render days of data collection
valid, a minimum awake wear time of 600 minutes (10 hours) was required.20 A minimum of four
valid days was required for analysis. Activity counts were categorized as: sedentary (<100
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counts/minute [cpm]), light intensity PA (LIPA; 100-<1952 cpm), moderate intensity PA (1952<5275 cpm), vigorous intensity PA (≥5275 cpm), or moderate and vigorous PA (MVPA; ≥1952
cpm).21,

22

Participants were categorized as meeting (i.e., ≥150 minutes of MVPA/week) or not

meeting (i.e., <150 minutes of MVPA/week) current PA guidelines for cancer survivors.23
Prolonged sedentary bouts were defined as uninterrupted sedentary bouts of ≥30 minutes.15, 24

Physical function and muscle strength
Measures of physical function included: (1) 400-meter walk as an indicator of
cardiorespiratory fitness,25 (2) repeated chair rise to assess lower extremity function,26 (3) 6-meter
usual pace walk to assess gait speed during daily activities, (4) 6-meter fast pace walk to assess
fastest self-selected gait speed and, (5) 6-meter backwards walk to assess dynamic balance.27,

28

With the exception of the 400-meter walk test, each test was performed three times, the fastest of
which was used for analysis. Measures of muscle strength included: (1) one repetition maximum (1RM) chest press and single-leg extension to measure dynamic upper and lower body muscle
strength, (2) handgrip strength test to assess isometric grip strength. Relative strength was
calculated by dividing absolute strength by body weight.

Body composition and muscle morphology
Body composition was measured by dual-energy x-ray absorptiometry (DXA, QDR-1500,
Hologic Discovery A, Waltham, MA). Participants’ regional and whole-body lean mass (LM), fat
mass, fat percentage, areal bone mineral content (BMC), and areal bone mineral density were
measured.

Peripheral

quantitative

computed

tomography

(pQCT,

XCT-3000,

Stratec

Medizintechnik, Pforzheim, Germany) scans were performed at 4%, 14%, 38% and 66% of tibial
length, (medial malleolus to medial condyle), distal to proximal, to measure muscle CSA and
muscle density, tibial mass, tibial CSA and tibial volumetric density across macroscopic (trabecular,
cortical and total) bone material. Stress-strain index was calculated as primary marker of bone
strength.29
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Statistical Analysis
Data were analyzed using SPSS version 23 (IBM Corp., NY, USA). Variables were assessed
for normality using the Shapiro-Wilk test. Results for frequency data are presented as
number/percentage,

and

mean/standard

deviation

for

normally

distributed

data,

or

median/interquartile range for non-normally distributed data. Non-normally distributed data were
analyzed using non-parametric tests. Differences between OCS and controls were measured using
the Pearson Chi square test, Likelihood Ratio or Fisher's exact test for categorical data, and the
independent t-tests or Mann-Whitney U tests for continuous variables. One-way analysis of
variance (ANOVA), Kruskal-Wallis and Bonferroni post hoc tests were used to compare NACT,
PDS and controls. Association between variables for OCS was determined by Pearson r or
Spearman rho correlations. All tests were two-tailed, with statistical significance set at an alpha
level of 0.05.

RESULTS
Participant Characteristics
Between July 2015 and May 2016, 20 OCS and 20 controls were recruited (Figure 1). The
OCS group was on average 5.3 (range 3-18) months post cancer treatment. All women had
undergone surgery, with 9 (45%) and 11 (55%) having received NACT or adjuvant chemotherapy,
respectively. Demographic, health and medical characteristics of participants are presented in Table
1. Most OCS and controls were overweight or obese and reported one or more comorbidity.
Compared to controls more OCS experienced shortness of breath (45% vs. 5%, p = 0.003) and
tingling or numbness in their extremities (45% vs. 0%, p <0.001), had a university degree (50% vs.
15%, p = 0.033) and were currently not working (20% vs. 0%, p = 0.031).
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Physical Activity and Sedentary Behavior
All OCS and controls provided ≥4 days of valid accelerometer data. One accelerometer
worn by a control participant was faulty, resulting in lost data. There were no differences between
OCS and controls for mean awake wear time (p = 0.301), or time/day spent in LIPA (p = 0.212) or
MVPA (p = 0.687) (Table 2). Thirty-five percent (n = 7) of OCS vs. 53% (n = 10) of controls
accrued a total MVPA time consistent with PA recommendations of ≥150 minutes/week. When
considering MVPA time in ≥10-minute bouts, 20% (n = 4) of OCS vs. 10.5% (n = 2) of controls
undertook ≥150 minutes/week.
Mean sedentary hours/day were similar for OCS and controls (p = 0.957). However,
compared to controls, OCS spent significantly more hours/day (3.1±1.3 vs. 2.4±0.7 h, p = 0.039)
and a significantly higher percentage of awake wear time/day (21.1±9.4 vs. 15.7±4.7%, p = 0.028)
in prolonged sedentary bouts.
Compared to controls, there were no significant differences in average time/day spent in
LIPA, MVPA or SB for NACT and PDS. However, NACT spent a significantly larger percentage
of awake wear time/day in prolonged sedentary bouts compared to controls (23.8±12.1 vs.
15.7±4.7%, p = 0.032, Bonferroni p = 0.028).

Physical function and muscle strength
The OCS group had a statistically non-significant slower median 400-meter walk time than
controls [256.5 (235.0-280.2) vs. 240.4 (225.4-254.6) sec, p = 0.091; Table 3]. The exclusion of an
extreme outlier (i.e., >3.0 x IQR) from the control group resulted in 400-meter walk time being
significantly slower for OCS vs. controls [256.5 (235.0-280.2) vs. 239.4 (224.6-251.9) sec, p =
0.041]. Compared to controls, OCS had significantly lower absolute (21.0±6.8 vs. 26.8±9.6 kg, p =
0.044) and relative (0.29±0.09 vs. 0.38±0.13 kg/kg body weight, p = 0.023) upper body muscle
strength. No significant differences were observed between groups for repeated chair rise, 6-m walk
tests, handgrip strength and lower body muscle strength.
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There were no significant differences between controls, NACT and PDS for functional or
strength outcomes. No adverse events were reported regarding any objective measures of physical
function and muscle strength.

Body composition and muscle morphology
Fat mass, LM, muscle CSA and muscle density were not significantly different between
OCS and controls (Table 4). Compared to controls, OCS had significantly higher areal BMC
(2262.3±305.1 vs. 2074.9±221.4 g, p = 0.047) and volumetric trabecular density (232.5±44.4 vs.
207.2±33.1 mg/cm³, p = 0.048).
There were no significant differences between either treatment group or controls in BMI, fat
mass, LM, muscle CSA or muscle density. However, compared to PDS, NACT had significantly
higher appendicular LM (18.9±3.8 vs. 15.9±2.3 kg, p = 0.045, Bonferroni p = 0.047; Figure 2) and
appendicular LM/height² (6.87±0.89 vs. 5.98±0.54 kg/m², p = 0.026, Bonferroni p = 0.045).

p= 0.513

p= 0.045*

p= 0.110

p= 0.342

Figure 3. Whole body and regional fat and lean mass of NACT, PDS and Control groups
*Statistical significance (p < 0.05), CI bars = 95%
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Associations of Activity Behavior with Objective Measures of Physical Function, Body
Composition and Muscle Morphology.
Total LIPA time/day (ρ = -0.481, p = 0.032), total MVPA time/day (ρ = -0.737, p < 0.001)
and total MVPA time/day in ≥10-minute bouts (ρ = -0.702, p = 0.001) were significantly inversely
correlated with 400-meter walk time.

Only total MVPA time/day in ≥10-minute bouts was

significantly correlated with repeated chair rise time (ρ = -0.519, p = 0.019). Total MVPA time/day
in ≥10 minute bouts correlated with muscle CSA (ρ = 0.473, p = 0.035) and muscle density (ρ =
0.438, p = 0.053). Total sedentary time/day (r = -0.713, p < 0.001), total prolonged sedentary
time/day (r = -0.449, p = 0.047), and number of prolonged sedentary bouts/day (r = -0.494, p =
0.027) were significantly inversely correlated with volumetric bone mineral density. Neither PA nor
sedentary time correlated with age or body composition in this sample of OCS.

DISCUSSION
There were five main findings from our cross sectional analysis: compared to controls, OCS:
(1) spent significantly more time/day in prolonged sedentary bouts; (2) had significantly lower
cardiorespiratory fitness and upper body strength; (3) had significantly higher areal BMC and
volumetric trabecular density; (4) had significant differences between treatment groups in
appendicular LM and appendicular LM/height², but were not significantly different in BMI, LM, fat
mass, and muscle morphology; and (5) for OCS, MVPA was associated with cardiorespiratory
fitness, lower extremity function and muscle CSA. Our findings suggest that OCS who engage in
more MVPA may experience benefits in terms of cardiorespiratory fitness, physical function and
muscle morphology.
In this study, OCS did not differ significantly from controls in time spent in LIPA, MVPA
and sedentary behavior. They did, however, spend significantly more time/day in prolonged
sedentary bouts. This is consistent with research in breast and lung cancer survivors.24, 30 Despite
similarities in PA participation between OCS and controls, our findings confirm that most OCS are
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insufficiently active, with only 20% meeting current PA guidelines for cancer survivors. In addition
to low PA levels, OCS were sedentary for a large percentage of awake time (66.8±7.6%), of which
3.1 hours was spent in prolonged bouts. Higher self-reported PA in cancer survivors is associated
with increased treatment tolerance, physical fitness and function, mental and physical health, and
reduced risk of recurrence and cancer-specific mortality in certain cancer groups.31 Regardless of
PA, sedentary time32 and prolonged sedentary bouts33,

34

are associated with adverse health

outcomes in adults and reduced quality of life in cancer survivors.14, 35 Promotion of regular PA and
breaking up of sedentary time in post-treatment OCS should be priorities in survivorship care.
We found that, compared to controls, OCS had significantly lower cardiorespiratory fitness
and upper body strength, but were similar in other aspects of physical function. Poor
cardiorespiratory fitness is associated with an increased risk of all-cause and cancer mortality.36, 37
Impaired cardiorespiratory fitness in OCS has been observed in previous research.38 Impaired
muscle strength negatively affects functional independence and quality of life, while impaired upper
body strength can have a debilitating effect on activities of daily living such as lifting, carrying, and
doing housework.39 The lack of significant differences in gait speed, balance and lower body and
handgrip strength was unexpected and needs confirmation. Exercise oncology interventions to
increase cardiorespiratory fitness and upper body strength in OCS are necessary and may help to
increase survival37 and preserve physical function and quality of life39 in this population.
Our results show that OCS were comparable to controls in terms of BMI, body weight, fat
and LM, and muscle morphology, but had significantly higher mean areal BMC and trabecular
density. The similarities in fat mass and muscle quantity and quality, and higher BMC and
trabecular density in OCS were unexpected. Many survivors in certain cancer groups experience
detrimental body composition changes (i.e., increase in fat mass, loss of muscle and/or bone mass)
due to the combined impact of cancer, treatment and reduced PA.40 Furthermore, previous OC
research reports low muscle mass and muscle density in 29-50% and 35% of women, respectively,
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at OC diagnosis41, 42 and bone loss in the first year after OC diagnosis.43 Future longitudinal studies
are warranted to assess body composition changes through the OC trajectory.
The differences observed between treatment groups in the current sample are notable. The
NACT group, but not PDS, spent a significantly larger percentage of awake wear time in prolonged
sedentary bouts compared to controls. Treatment groups did not significantly differ in terms of
physical function or muscle strength, but exhibited body composition differences. Significantly
higher appendicular LM in NACT did not translate into improved function or muscle strength,
possibly due to their non-significantly higher fat mass (34.0±8.3 vs. 26.4±8.8 kg, p = 0.110).
Parallels in physical function and strength might also be explained by similarities in muscle quality,
confirming the previously established association between muscle quality, and physical function
and muscle strength.44, 45 It is possible that the NACT and PDS groups may have had significantly
different physiological profiles pre-treatment and that our findings are due to selection bias. The
observed differences between treatment groups are novel and require further investigation in large
prospective studies. If confirmed, different exercise intervention strategies may be required based
on treatment regimen.
Our study indicates a positive relationship between all intensities of objective PA in OCS
and cardiorespiratory fitness, while MVPA in ≥10-minute bouts positively correlated with lower
extremity function and muscle CSA. This finding implies that any PA is better than none, but
highlights the additional advantages of higher intensity, prolonged PA bouts. The moderate
correlation between MVPA and muscle morphology requires further investigation, but is notable in
light of research suggesting an association between low muscle mass46 and density42, 47 at diagnosis
and mortality in OCS. All sedentary outcome measures were negatively correlated with volumetric
bone mineral density, confirming the importance of minimizing SB to maintain good bone health in
OCS.
This study has important strengths and limitations that should be considered. To our
knowledge, it is the first study to provide a comprehensive cross-sectional analysis of objectively
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measured activity behavior, physical function and body composition in post-treatment OCS. Our
sample of OCS is relatively homogenous in terms of disease and treatment stage. A further strength
of the study is the inclusion of an age-matched control group. However, the small sample size limits
interpretation, as the study was underpowered to detect small, but potentially meaningful
differences between groups. Women with a greater interest in PA may have enrolled in the study
resulting in potential selection bias. Lastly, due to the study’s cross-sectional design, no inferences
can be made about changes over time, or causality. Longitudinal studies are needed to objectively
assess changes in OCS’ activity behaviors and physiological status and to investigate the
relationship between, and the impact of these changes over time. Physiological differences between
NACT and PDS also require further investigation.

CONCLUSION
In this cross-sectional study, OCS spent more time in prolonged sedentary bouts, had lower
cardiorespiratory fitness and upper body strength, and higher areal BMC and volumetric trabecular
density compared to age-matched controls. Women treated with NACT had higher appendicular
LM compared to those treated with PDS, suggesting that different exercise intervention approaches
could be required depending on treatment regimen.

In OCS MVPA was associated with

cardiorespiratory fitness, lower extremity function and muscle cross-sectional area, and sedentary
behavior was consistently negatively correlated with bone mineral density.

Collectively, our

findings support the need for future studies in OCS, testing the efficacy of exercise medicine
interventions to increase MVPA, reduce SB, and improve cardiorespiratory fitness and muscular
strength.
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Table 1. Demographic, medical and health characteristics of Cancer and Control groups

Cancer group
(n = 20)
63.2±8.9
n
%
15
75
5
25

Age
Relationship status
Partnered
Not partnered
Educational attainment
Completed secondary school
3
Post-secondary certificate/diploma
7
University degree
10
Employment status
Currently working
7
Currently not working
4
Retired
9
Smoking Status
Non smoker
13
Past smoker
5
Current smoker
2
Alcohol drinks per week
None
8
1-7 units
9
≥8 units
3
Body mass index
Normal (<25.0 kg/m²)
7
Overweight (≥25.0-29.9 kg/m²)
7
Obese (≥30.0 kg/m²)
6
Number of comorbidities
None
5
One
8
≥Two
7
Current symptoms/side-effects
Shortness of breath
9
Tingling, numbness, loss of feeling§
9
Swelling of feet and ankles
8
Pains or cramps in legs
10
Chest discomfort
2
§Cancer group n = 18 due to missing data
*Statistical significance (p < 0.05)

Control group
(n = 20)
63.0±9.1
n
%
13
65
7
35

p-value
0.944
0.490

0.033*
15
35
50

9
8
3

45
40
15
0.031*

35
20
45

12
0
8

60
0
40
0.055

65
25
10

9
11
0

45
55
0
0.791

40
45
15

7
11
2

35
55
10
0.924

35
35
30

8
7
5

40
35
25
0.426

25
40
35

4
5
11

20
25
55

45
45
40
50
10

1
0
6
8
2

5
0
30
40
10
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0.003*
<0.001*
0.507
0.525
1.000

Table 2. Accelerometer-assessed sedentary time and physical activity in Cancer, Control, NACT and PDS treatment groups

Waking wear time, h/day
Sedentary behavior (<100 cpm)
Total time, h/day
Time spent in SB (% of awake time)
Time in ≥30 min bouts, h/day
Time in ≥30 min SB bouts (% of awake time)
Number of ≥30 min bouts/day
Light physical activity (100 to <1952 cpm)
Total time, h/day
Time spent in light PA (% of awake time)
Moderate physical activity (1952-<5275
cpm)
Total time, min/day
Vigorous physical activity (≥5275 cpm)
Total time, min/day
MVPA
Total time, min/day
Time in MVPA (% of awake time)
Consistent with ≥150 minutes/week [n (%)]
Time in ≥10 min bouts, min/day
Consistent with ≥150 minutes/week [n (%)]
Time in ≥10 min MVPA bouts (% of awake
time)

Cancer group
(n = 20)
14.8±1.1

Control group
(n = 19)
15.2±1.4

p-value
T-test
0.301

NACT group
(n = 9)
14.7±1.2

PDS group
(n = 11)
14.9±1.1

p-value
ANOVA
0.546

9.9±1.1
66.8±7.6
3.1±1.3
21.1±9.4
3.9±1.4

9.9±1.1
64.7±4.5
2.4±0.7
15.7±4.7
3.1±0.8

0.957
0.301
0.039*
0.028*
0.055

9.7±1.4
66.5±10.2
3.5±1.7
23.8±12.1
4.2±1.7

10.0±0.9
67.1±5.2
2.8±1.0
18.9±6.2
3.6±1.1

0.864
0.577
0.052
0.032*
0.080

4.6±1.2
30.6±6.6

5.0±0.8
32.6±4.1

0.212
0.278

4.6±1.5
31.1±9.0

4.5±0.8
30.2±4.2

0.455
0.527

17.4 (34.4)†

24.7 (22.3)†

0.667‡

21.7±18.2

24.0±18.4

0.893

0.0 (0.1)†

0.0 (0.0)†

0.687‡

0.0(0.3)†

0.0 (0.1)†

0.813‡‡

17.6 (34.5)†
2.6±2.0
7 (35)
5.2 (14.7)†
4 (20)

24.7 (26.9)†
2.7±1.5
10 (52.6)
6.1 (8.7)†
2 (10.5)

0.687‡
0.776
0.267
0.835‡
0.661††

21.8±18.2
2.4±2.0
3 (33.33)
3.1 (16.5)†
2 (22.2)

24.3±18.8
2.7±2.1
4 (36.36)
5.6 (16.4)†
2 (18.2)

0.861
0.906
0.791‡
0.693

0.6 (1.6)†

0.7 (0.9)†

0.857‡

0.4 (1.7)†

0.6 (1.7)†

0.804‡
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Number of ≥10 min bouts/day

0.3 (0.6)†

0.3 (0.4)†

0.647‡

0.3 (0.8)†

0.3 (0.7)†

0.778‡

NACT = neoadjuvant chemotherapy; PDS = primary debulking surgery; cpm = counts per minute on the vertical axis of hip-worn Actigraph
accelerometer; SB = sedentary bouts; PA = physical activity; MVPA = moderate-and-vigorous physical activity.
Values are presented as mean±SD unless otherwise specified
†Median (interquar le range), ‡Mann-Whitney test, ††Fisher's Exact
*Statistical significance (p < 0.05)
**NACT spent a significantly larger % of awake wear time/day in prolonged sedentary bouts compared to Control group (Bonferroni p = 0.028)
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Table 3. Physical function and muscle strength values for Cancer, Control, NACT and PDS treatment groups

Cancer group
(n = 20)
Physical function
400-meter walk (s)
400-meter walk (s)¶
Repeated chair rise (s)
Repeated chair rise (s)¶¶
6-meter walk usual pace (s)
6-meter walk fast pace (s)
6-meter walk fast pace (s)¶
6-meter backwards walk (s)
Muscle strength
Absolute strength
Chest press 1RM (kg)§
Single leg extension 1RM (kg)§§
Hand grip strength, (kg)§§§
Relative strength
Chest press§
Single leg extension§§
Hand grip strength§§§

Control group
(n = 20)

p-value
T-test

256.5 (45.2)†
256.5 (45.2)†
12.0 (2.8)†
11.8 (2.2)†
4.2±0.5
3.2 (0.4)†
3.2 (0.4)†
21.0±5.7

240.4 (29.3)†
239.4 (27.4)†
11.0 (4.0)†
11.0 (4.0)†
4.2±0.7
3.1 (0.4)†
3.1 (0.3)†
19.7±4.2

0.091‡
0.041‡*
0.242‡
0.351‡
0.817
0.277‡
0.158‡
0.408

21.0±6.8
24.1±9.1
24.4±6.6

26.8±9.6
25.2±8.4
26.8±7.0

0.29±0.09
0.33±0.10
0.33±0.08

0.38±0.13
0.36±0.12
0.38±0.09

NACT group
(n = 9)

PDS group
(n = 11)

p-value
ANOVA

256.7 (22.8)†
256.7 (22.8)†
11.8 (4.0)†
11.8 (4.0)†
4.1±0.4
3.2 (0.4)†
3.2 (0.4)†
20.9±4.5

244.0 (54.1)†
244.0 (54.1)†
12.1 (3.0)†
11.9 (2.1)†
4.2±0.6
3.1 (0.5)†
3.1 (0.5)†
21.1±6.7

0.141‡‡
0.072
0.418‡‡
0.614‡‡
0.918
0.544‡‡
0.362
0.711

0.044*
0.724
0.273

23.3±7.4
26.9±9.4
25.2±6.9

18.8±5.7
21.4±8.4
23.8±6.7

0.070
0.384
0.500

0.023*
0.342
0.112

0.29±0.60
0.33±0.07
0.31±0.05

0.29±0.12
0.32±0.13
0.35±0.10

0.078
0.640
0.156

NACT = neoadjuvant chemotherapy; PDS = primary debulking surgery; 1RM = one repetition maximum.
Values are presented as mean±SD unless otherwise specified
¶Extreme outlier removed from Control group, ¶¶Extreme outlier removed from Cancer group
†Median (interquar le range), ‡Mann-Whitney test, ‡‡Kruskal-Wallis test
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Relative strength was calculated by dividing absolute strength by body weight
§Cancer group n = 18, Control group n = 19, PDS group n = 9 due to inability complete upper body strength measures
§§Cancer group n = 18, Control group n = 18, PDS group n = 9 due to inability complete lower body strength measures
§§§Control group n = 19 due to inability complete hand grip strength measures
*Statistical significance (p < 0.05)
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Table 4. Body composition and muscle density values for Cancer, Control, NACT and PDS treatment groups

BMI
Height (cm)
Waist to hip ratio
DXA
Body weight (kg)
Whole body fat mass (kg)
Trunk fat mass (kg)
Whole body fat percentage (%)
Whole body LM (kg)
Appendicular LM (kg)
Appendicular LM/height²
(kg/m²)
Whole-body aBMC (g)§
Whole-body aBMD (g/cm²)§
pQCT
Muscle area (mm²)
Muscle density (mg/cm³)
Tibial mass g/cm
Tibial area (mm²)
Tibial vBMD (mg/cm³)
Trabecular area (mm²)
Trabecular vBMD (mg/cm³)
Cortical area (mm²)

Cancer group
(n = 20)
27.4±4.5
163.9±7.1
0.84 (0.7)†

Control group
(n = 20)
27.2±4.5
162.9±9.4
0.84 (0.10)†

p-value
T-test
0.888
0.657
0.947‡

NACT group
(n = 9)
29.57±3.90
165.3±6.5
0.84 (0.05)†

PDS group
(n = 11)
25.64±4.25
162.7±7.8
0.84 (0.09)†

p-value
ANOVA
0.139
0.630
0.798‡‡

74.2±15.4
29.8±9.2
13.5±5.0
39.4±5.3
42.0 (8.5)†
17.3±3.4

72.2±10.6
28.0±7.9
12.5±4.6
38.1±6.6
40.8 (8.0)†
17.7±2.2

0.632
0.500
0.520
0.491
0.862‡
0.610

81.1±14.7
34.0±8.3
15.0±3.8
41.6±4.7
44.7±7.5
18.9±3.8

68.5±14.1
26.4±8.8
12.2±5.6
37.6±5.4
40.0±5.6
15.9±2.3

0.086
0.110
0.342
0.264
0.513‡‡
0.045**

6.4±0.8
2262.3±305.1
1.08±0.10

6.7±0.8
2074.9±221.4
1.05±0.08

0.256
0.047*
0.263

6.9±0.9
2393.0±267.7
1.11±0.10

6.0±0.5
2157.7±304.6
1.06±0.10

0.026**
0.025***
0.257

5862.5±1184.4
72.4 (5.8)†
3.0±0.5
665.0±92.5
555.9±72.5
491.8±70.5
232.6±44.4
218.6±32.7

6088.4±708.1
74.2 (3.9)†
2.8±0.3
632.5±64.6
532.5±53.3
464.3±53.8
207.3±33.2
212.7±23.1

0.469
0.221‡
0.940
0.205
0.252
0.173
0.048*
0.514

6312.1±1455.4
72.8 (4.1)†
3.2±0.5
675.6±103.4
579.4±73.2
495.42=±76.0
252.9±42.7
228.9±33.7

5494.6±800.0
72.0 (7.3)†
2.9±0.4
656.4±86.7
536.6±69.2
488.9±69.4
216.0±40.2
210.1±30.8

0.131
0.423‡‡
0.062
0.394
0.170
0.390
0.015***
0.273
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Cortical vBMD (mg/cm³)
SSI (mm³)

1110.9±47.7
1511.7 (287.9)†

1101.4±33.6
1468.6 (244.5)†

0.469
0.369‡

1124.2±46.2
1654.3±332.7

1100.0±48.3
1437.2±208.7

0.331
0.063

NACT = neoadjuvant chemotherapy, PDS = primary debulking surgery, BMI = body mass index, FM = fat mass, LM = lean mass,
aBMC = areal bone mineral content, aBMD = areal bone mineral density, vBMD = volumetric bone mineral density, SSI = stress-strain index.
Values are presented as mean±SD unless otherwise specified
†Median (interquar le range), ‡Mann-Whitney test, ‡‡Kruskal-Wallis test
§Cancer group n = 18, Control group n = 17, NACT Group n = 8, PDS Group n = 10 due to metallic surgical implants
*Statistical significance (p < 0.05)
**Appendicular LM (kg) and appendicular LM/height² (kg/m²) was significantly higher in NACT than PDS, Bonferroni p = 0.047 and 0.045, respectively
***BMC (g) and trabecular density (mg/cm³) was significantly higher in NACT than in Control group, Bonferroni p = 0.021 and 0.013, respectively
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Chapter 4
OBSERVATIONAL STUDY

“Associations of objective activity behaviors and physiological characteristics with
health-related quality of life and pelvic floor dysfunction in advanced-stage ovarian
cancer survivors”

Schofield C, Newton RU, Galvão DA, Cohen PA, McVeigh JA, Mohan GR, Tan J, Salfinger SG,
Straker LM, Peddle-McIntyre CJ. Manuscript prepared for submission to Supportive Care in
Cancer, October 2017.
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ABSTRACT
Purpose: Little is known about the relationship between health-related quality of life (HRQoL),
pelvic floor dysfunction (PFD) and modifiable lifestyle and physiological factors for ovarian cancer
survivors (OCS). This study aimed to compare post-treatment advanced-stage OCS with agematched controls on measures of HRQoL and PFD. Associations between HRQoL, PFD, objective
activity behaviors, physical function and body composition in OCS were also examined.
Methods: Twenty advanced-stage OCS and 20 controls completed questionnaires assessing
HRQoL (SF-36) and PFD (Australian Pelvic Floor Questionnaire), and underwent objective
assessments of activity behavior (7-day accelerometry), physical function (400-meter walk,
repeated chair rise, 6-meter usual-pace walk, 1-repetition maximum chest press and single leg
extension) and body composition (dual-energy x-ray absorptiometry).
Results: Compared to controls, OCS had worse physical HRQoL (-4.3 median difference, p=
0.013), but equivalent self-reported PFD, indicated by combined bladder, bowel and pelvic organ
prolapse symptoms (0.89 mean difference, p= 0.277). In OCS physical HRQoL was significantly
negatively associated with PFD (r= 0.468, p= 0.043). Decreased physical HRQoL and increased
PFD were significantly associated with less moderate-and-vigorous physical activity in ≥ 10-minute
bouts (ρ= 0.627, p= 0.003; ρ= -0.457, p= 0.049), more sedentary time (r= -0.449, p= 0.047; r=
0.479, p= 0.038) and slower 400-meter walk time (ρ= -0.565, p= 0.022; ρ= 0.504, p= 0.028).
Conclusions: Post-treatment advanced-stage OCS have decreased physical HRQoL, which is
associated with modifiable factors such as PFD, moderate-and-vigorous physical activity, sedentary
time and objective physical function. This highlights the need for ongoing supportive care and
multidisciplinary interventions after first-line OC treatment.
Key Words: Ovarian cancer, Health-related quality of life, Pelvic floor dysfunction, Moderate-andvigorous physical activity (MVPA), Sedentary time
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INTRODUCTION
Ovarian cancer (OC) is the seventh most common cancer among women worldwide.1
Between 70% and 75% of OC cases are diagnosed at an advanced stage.2 Treatment in advancedstage OC is often palliative and aimed at controlling disease and treatment related symptoms and
side-effects, whilst prolonging survival with optimal quality of life.3 As such, health-related quality
of life (HRQoL) in women with OC has received increasing attention in the last decade.4
Although research involving measurement of HRQoL in ovarian cancer survivors (OCS) is
increasing, interpretation of results can be challenging due to heterogeneity of study design and
participant groups (e.g., different disease stages and treatments). Furthermore, existing studies
mostly investigate HRQoL in long-term OCS (≥ five years post-diagnosis) or in women on
treatment, with little information for OCS following first-line treatment.5 Few studies have
compared HRQoL between OCS and age-matched controls drawn from the same community.6, 7
Health-related QoL in OCS is known to be negatively impacted by persistent treatmentrelated side-effects.4 Poorer HRQoL has been linked with lifestyle factors such as obesity and
insufficient self-reported physical activity (i.e., <150 minutes of moderate-and-vigorous physical
activity [MVPA] per week).8,

9

However, associations of HRQoL with body composition and

objectively measured activity behaviors (i.e., physical activity [PA] and sedentary behavior [SB])
have not yet been examined. Furthermore, although most QoL instruments measure self-rated
physical function, the relationship between objectively measured physical function and HRQoL in
OCS has not been explored previously.
Pelvic floor dysfunction (PFD) is widely recognized as a public health issue with significant
impact on HRQoL for millions of women globally.10, 11 Although gynecological cancer treatment is
often considered a risk factor for increased PFD, this association has not been firmly established.12
Pelvic floor dysfunction is a general term that refers to clinical problems involving different organ
systems in the same anatomical area. It encompasses symptoms associated with bladder, bowel and
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pelvic organ prolapse (POP), and sexual dysfunction.13 Sexual dysfunction and gastrointestinal
issues such as constipation, diarrhea and indigestion after OC treatment are well documented,14, 15
but data regarding the prevalence, severity and impact of PFD in OCS are limited.16
To design and implement tailored interventions aimed at improving HRQoL for OCS, it is
crucial to understand the relationship between HRQoL and modifiable factors such as PFD, activity
behaviors, physical function and body composition. We have previously reported that, compared to
age-matched controls, OCS spent significantly more time/day in prolonged sedentary bouts of ≥30
minutes and had significantly lower cardiorespiratory fitness and upper body strength.17 In this
report we extend our previous analysis to: (1) compare HRQoL and PFD in OCS who had
completed first-line treatment to age-matched controls; (2) investigate associations between HRQoL
and PFD in OCS; and (3) explore associations of HRQoL and PFD with objective activity
behaviors, physical function and body composition in OCS.

METHODS
Setting and participants
The study was conducted at the Exercise Medicine Research Institute at Edith Cowan
University and St John of God Subiaco Hospital in Perth, Western Australia. The Human Research
Ethics Committees of both institutions granted ethical approval (Ref. No. 12511, 23/4/2015; Ref.
No. 815, 12/6/2015).

Ovarian cancer survivors were eligible for participation if they had

histologically confirmed stage III–IV epithelial OC, were 3-24 months post completion of first-line
treatment, were ≥18 years of age, received approval from the treating oncologist or general
practitioner, were able to walk 400 meters, were proficient in English, had no existing or suspected
bone metastases, no acute illness or any musculoskeletal, cardiovascular or neurological disorder
that could put them at risk during exercise testing. The same non-cancer eligibility criteria applied
for controls. All participants provided written informed consent.
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Outcome Measures
Demographic, medical, HRQoL and pelvic floor data were obtained by self-report
questionnaires. Additional information regarding cancer diagnosis and treatment were collected
from OCS. All anthropometric measures (height and body weight to calculate body mass index
[BMI], waist and hip circumference to calculate waist-to-hip ratio), body composition and objective
functional data were collected at the Exercise Medicine Research Institute by one investigator (CS).

Health-related Quality of Life
Health-related QoL was measured using the Medical Outcomes Study Short Form-36 (MOS
SF-36) questionnaire.18 The SF-36 is a generic instrument that comprises eight subscales measuring
Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning,
Role-Emotional and Mental Health. Subscale scores were combined into a physical component
summary score (PCS) and a mental component summary score (MCS).19 All scores were
standardized to 1998 general US population norms.20 Higher scores reflect better HRQoL in the
domain being measured.20 The SF-36 has been established as a reliable and valid measure of QoL21
and is often used to assess QoL of OCS.4

Pelvic Floor Dysfunction
Self-reported PFD was measured with the Australian Pelvic Floor Questionnaire (APFQ).22,
23

The APFQ has four subscales, with a range of questions each, to assess bladder, bowel and POP

symptoms, and sexual function.

Bladder, bowel and POP symptom scores out of 10 were

calculated. We did not calculate sexual function scores due to the large percentage of women (55%
of all participants) indicating sexual inactivity and thus not completing the section. Bladder, bowel
and POP symptom scores out of 10 were added for a combined bladder-bowel-POP symptom score
out of 30, hereafter referred to as the Pelvic Floor Score. Higher scores in all domains indicate that
women are experiencing more symptoms and thus more dysfunction. The APFQ has been indicated
as valid and reliable measure of all four pelvic floor domains.22, 23
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Physical Activity and Sedentary Behavior
Objective PA and sedentary time were measured over a seven-day period with a hip-worn
tri-axial accelerometer (ActiGraph GT3X+, ActiGraph Corp, FL, USA). Data processing details
have been reported previously.17 Activity counts were categorized as: sedentary (<100
counts/minute [cpm]), light intensity PA (100-<1952 cpm), moderate intensity PA (1952-<5275
cpm), vigorous intensity PA (≥5275 cpm), or MVPA (≥1952 cpm).24, 25 Moderate-and-vigorous PA
was assessed as total MVPA time/day and MVPA time/day in strict ‘bouts’ of ten consecutive
minutes or more with no interruption.

Physical Function and Muscle Strength
Objective measures of physical function included: (1) 400-meter walk as an indicator of
cardiorespiratory fitness,26 (2) repeated chair rise to measure lower extremity function,27 (3) 6-meter
usual pace walk to measure gait speed during daily activities, (4) 6-meter backwards walk to
measure dynamic balance.28,

29

All tests, except for the 400-meter walk test, were performed in

triplicate and the fastest of each was used for analysis. Upper and lower body muscle strength was
measured with one repetition maximum (1-RM) chest press and single leg extension (dominant leg
unless contraindicated), respectively. Relative strength was calculated by dividing absolute strength
by body weight.

Body Composition and Muscle Morphology
Body composition was measured by dual-energy x-ray absorptiometry (DXA, QDR-1500,
Hologic Discovery A, Waltham, MA). Participants’ regional and whole-body lean mass, fat mass,
fat percentage, areal bone mineral content and areal bone mineral density were measured.
Peripheral quantitative computed tomography (pQCT, XCT-3000, Stratec Medizintechnik,
Pforzheim, Germany) scans were performed to measure muscle cross-sectional area and density,
and tibial mass, cross-sectional area and volumetric density across macroscopic (trabecular, cortical
and total) bone material.
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Statistical Analysis
Data were analyzed using SPSS version 23 (IBM Corp., NY, USA). The Shapiro-Wilk test
was used to assess normality of variables. Results for frequency data are presented as
number/percentage,

and

mean/standard

deviation

for

normally

distributed

data,

or

median/interquartile range for non-normally distributed data. Non-parametric tests were used to
analyze non-normally distributed data. Probability of significant differences between OCS and
controls were determined using the Pearson Chi square test, Likelihood Ratio or Fisher's exact test
for categorical data, and independent t-tests or Mann-Whitney U tests for continuous variables.
Pearson r or Spearman rho correlations were used to determine association between variables for
OCS. All tests were two-tailed, with statistical significance set at an alpha level of 0.05.

RESULTS
Participant recruitment details and characteristics have been reported previously.17 Briefly,
20 OCS and 20 controls were recruited between July 2015 and May 2016. Eligible OCS were
recruited via the consulting rooms of three gynecologic oncologists. Controls were recruited via
snowball sampling, from staff at a local university and hospital, and from the wider community.
The OCS-group was on average 5.3 months (range 3-18) post cancer treatment. All OCS had
undergone surgery, with 9 (45%) and 11 (55%) having received neoadjuvant or adjuvant
chemotherapy, respectively. There were no differences between OCS and controls for age (63.2±8.9
vs. 63.0±9.1 years; p = 0.944) or BMI (27.4±4.5 vs. 27.2±4.5 kg/m²; p = 0.888). Most OCS and
controls reported one or more comorbidities (75% vs. 80%; p = 0.426). More OCS than controls
had obtained a university degree (50% vs. 15%; p = 0.033), while more controls than OCS were
currently working (100% vs. 80%; p = 0.031).

Health-related Quality of Life and Pelvic Floor Dysfunction
Compared to controls, OCS had significantly lower scores in three of the four physical
component subscales, namely Physical Functioning (p = 0.024), Role Physical (p = 0.023) and
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General Health (p = 0.021), as well as PCS (p = 0.013). No statistical differences were observed
between OCS and controls for any of the mental component subscales, or MCS (Figure 4).
An extreme outlier (i.e., >3.0 x IQR) was removed from the control group for the Pelvic
Floor Score. No significant differences were observed between OCS and controls for Bladder,
Bowel or POP Scores, or the Pelvic Floor Score. Seventy percent (n = 14) of OCS vs. 40% (n = 8)
of controls were sexually inactive (chi square = 3.636; p = 0.057) (Table 5).

Associations between Health-related Quality of Life and Pelvic Floor Dysfunction in
Ovarian Cancer Survivors
Bladder Score was significantly inversely correlated with Physical Functioning (ρ = -0.451;
p = 0.046), Role Physical (r = -0.533; p = 0.016), General Health (r = -0.475; p = 0.034) and PCS (r
= -0.520; p = 0.019). Bowel Score was significantly inversely correlated with Physical Functioning
(ρ = -0.478; p = 0.039), Role Physical (r = -0.479; p = 0.038), General Health (r = -0.571; p =
0.011), Vitality (r = -0.554; p = 0.014), Role Emotional (ρ = -0.490; p = 0.033), Mental Health (r = 0.499; p = 0.030) and PCS (r = -0.473; p = 0.041). Pelvic Floor Score was significantly inversely
correlated with Physical Functioning (ρ = -0.509; p = 0.026), Role Physical (r = -0.482; p = 0.036),
General Health (r = -0.558; p = 0.013), Role Emotional (ρ = -0.509; p = 0.026) and PCS (r = -0.468;
p = 0.043).

Associations between Health-related Quality of Life and Activity Behavior, Physical
Function and Body Composition in Ovarian Cancer Survivors
We have previously conducted a comprehensive cross-sectional assessment of objectively
measured activity behavior and physical function, and body composition in OCS, compared to agematched controls. Results are reported elsewhere.17
In this study MVPA time/day was significantly correlated with Physical Functioning (ρ =
0.532; p = 0.016), Bodily Pain (ρ = 0.521; p = 0.018), General Health (ρ = 0.511; p = 0.021), and
64

PCS (ρ = 0.606; p = 0.005). Moderate-and-vigorous PA time/day in ≥ 10-minute bouts was
significantly correlated with Physical Functioning (ρ = 0.499; p = 0.025), Bodily Pain (ρ = 0.531; p
= 0.016) and PCS (ρ = 0.627; p = 0.003). Sedentary time/day was significantly inversely correlated
with Physical Functioning (ρ = -0.578; p = 0.008), Role Physical (r = -0.454; p = 0.045), General
Health (r = -0.720; p = <0.001), Vitality (r = -0.656; p = 0.002), Mental Health (r = -0.636; p =
0.003) and PCS (r = -0.449; p = 0.047).
Six-meter usual walk time was significantly inversely correlated with Physical Functioning
(ρ = -0.655; p = 0.002) and PCS (r = -0.588; p = 0.006). Four hundred meter walk time was
significantly inversely correlated with Physical Functioning (ρ = -0.608; p = 0.004), Bodily Pain (ρ
= -0.514; p = 0.020) and PCS (ρ = -0.565; p = 0.009) Relative lower body strength was significantly
correlated with PCS (r = 0.537; p = 0.022).
Neither BMI nor any of the body composition components were correlated with any of the
HRQoL domains.

Associations between Pelvic Floor Dysfunction, and Activity Behavior, Physical
Function and Body Composition in Ovarian Cancer Survivors
Moderate-and-vigorous PA time/day in ≥ 10-minute bouts, but not total MVPA time/day,
was significantly inversely correlated with Pelvic Floor Score (ρ = -0.457; p = 0.049). Sedentary
time/day was significantly correlated with Bowel Score (r = 0.531; p = 0.019) and Pelvic Floor
Score (r = 0.479; p = 0.038).
Six-meter usual walk time was significantly correlated with Bladder (r = 0.729; p = <0.001)
and Pelvic Floor Scores (r = 0.514; p = 0.024). Four hundred meter walk time was significantly
correlated with Bladder (ρ = 0.554; p = 0.011) and Pelvic Floor Scores (ρ = 0.504; p = 0.028).
Relative upper and lower body strength were significantly inversely correlated with Bladder Score
(r = -0.477; p = 0.045, r = -0.541; p = 0.020)
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No significant correlations were observed between BMI or components of body
composition, and PFD.

DISCUSSION
The purpose of this cross-sectional study was to assess HRQoL and PFD in advanced-stage
OCS, compared to age-matched controls. A secondary objective was to investigate associations
between HRQoL, PFD, objective activity behaviors and physical function, and body composition in
OCS. We found that OCS had worse physical HRQoL, but equivalent self-reported PFD compared
to controls. Ovarian cancer survivors who reported more symptoms related to PFD had lower
physical HRQoL. Worse physical HRQoL and greater PFD in OCS were associated with less
MVPA in ≥ 10 minute bouts, more sedentary time and lower levels of objective physical function.
Physical HRQoL, but not PFD, was positively associated with total MVPA time/day.
Our sample of OCS reported significantly lower physical and functional, but equivalent
social, emotional and mental HRQoL compared to age-matched controls from the same community.
Our findings are not consistent with a recent study which reported that stages I-IV OCS one year
post-diagnosis have comparable HRQoL to the general US female population.5 This may be due to
the inclusion of women with early-stage disease who may have had better physical function5
compared to only advanced-stage OCS in our study. We found no research that investigated
HRQoL in advanced-stage OCS early after completion of first-line treatment. Studies comparing
HRQoL of OCS and controls drawn from the same community have included stage I-IV OCS more
than five years since diagnosis, with mixed results.30, 31 Our findings suggest that advanced-stage
OCS following first-line treatment experience physical health and functional limitations that
negatively impact their daily living. Although this finding needs to be substantiated in larger
studies, it highlights the need for ongoing care to address physical and functional limitations after
completion of first-line OC treatment.
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To our knowledge, this is the first study to examine the relationships between HRQoL,
objectively measured activity behaviors and physical function, and body composition in OCS.
Health-related QoL in OCS has previously been associated with symptom burden, self-reported PA
and obesity.4, 8 We found that better physical HRQoL was also associated with more MVPA, less
sedentary time and better objective physical function in OCS. An association between HRQoL and
MVPA, but not sedentary time, has been previously shown in colon cancer survivors.32 Our data
suggests that interventions aimed at increasing MVPA, reducing sedentary time and improving
physical function could improve HRQoL for OCS.
Advanced-stage OCS in this study reported equivalent levels of PFD, as indicated by bladder,
bowel and POP symptoms, but 30% higher rates of sexual inactivity, compared to controls.
Research in gynecological cancer survivors indicates that rates of urinary incontinence and other
pelvic floor symptoms are high even before commencement of cancer treatment; however, the
prevalence of symptoms does not differ compared to non-cancer controls.12, 33 Studies investigating
PFD after completion of gynecological cancer treatment suggest that, compared to controls,
gynecological cancer survivors have equivalent urinary incontinence and POP, but more fecal
incontinence and sexual inactivity.6, 7 One reason for the difference between our observation and
findings in gynecological cancer survivors regarding bowel symptoms could be related to different
treatment regimens. Radiation therapy is not used in first-line OC treatment, but is common in
endometrial and cervical cancer treatment,34 and is associated with detrimental radiation-induced
gastrointestinal toxicities.35 Although clearly OCS may experience severe and debilitating PFD, our
data suggest that the prevalence of self-reported PFD is not different in advanced-stage OCS
compared to similarly-aged women with comparable BMI in the general population.
It is notable that OCS who experienced more PFD also reported worse HRQoL, consistent
with research in the general population of women.10,

11

Existing evidence indicates that some

aspects of PFD are treatable, for example, pelvic floor muscle training has been shown to be
effective in treating urinary incontinence.36 Evidence-based education and screening of OCS for
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PFD at diagnosis and throughout their cancer journey is required, with appropriate referral for
assessment and treatment when indicated. The level of PFD experienced by individual OCS should
guide recommendations and precautions for physical activity participation, exercise testing and
exercise training.
In the general female population, pelvic floor dysfunction is associated with modifiable risk
factors such as low self-reported PA levels,37 reduced physical function38 and obesity.39 We found
that OCS with more PFD spent less time/day doing MVPA in ≥ 10-minute bouts. This is consistent
with results from a recent study indicating an inverse association between MVPA in ≥ 10-minute
bouts and PFD in middle-aged women from the general population.40 These findings suggest that
the prevalence of PFD may not affect participation in light, informal PA associated with daily
living, but negatively affects participation in planned, purposeful and repetitive MVPA (i.e.,
exercise) in ≥ 10-minute bouts, which is associated with optimal health benefits.41 In our study OCS
with more PFD also accrued more sedentary time/day and had worse objective physical function.
Future research is needed to determine to what extent increased PFD in OCS affects physical
activity participation and sedentary behavior, and subsequently objective physical function. Best
current evidence suggests that most PA does not harm the pelvic floor; however, more research is
needed to fill existing knowledge gaps.37 For OCS with multiple pelvic floor symptoms,
multidisciplinary interventions aimed at treating PFD while incorporating exercise training could be
beneficial. Conversely, findings from our study suggest that many OCS who have completed firstline treatment experience only a few mild pelvic floor symptoms (e.g., 58% of OCS scored ≤5/30
for combined bladder, bowel and POP symptoms). Physical activity and exercise participation for
these OCS should not be restricted based on pelvic floor concerns, especially considering potential
improvements in cancer survivors’ HRQoL after participating in exercise programs.42
Notably, in this study HRQoL and PFD in OCS were not associated with BMI or
components of body composition (e.g., lean mass, fat mass or fat percentage). This was a surprising
finding considering that existing evidence supports associations between obesity and decreased
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HRQoL in OCS8 and between obesity and PFD in the general population.39, 43 These findings may
be due to our study being underpowered to detect such associations and require further investigation
in larger prospective studies.
Limitations of the study include the cross-sectional study design, which does not allow
inferences to be made regarding changes over time or causality. As we did not adjust data for
multiple comparisons, three of our findings could be due to chance. The small sample size limits
generalization of results. An objective measurement of PFD (e.g., ultrasound) and/or the inclusion
of questions regarding previous treatments and known risk factors (e.g., parity and vaginal birth) for
PFD would have provided a better understanding of PFD in both OCS and controls. We
acknowledge the possibility of recruitment bias, as women with severe pelvic floor symptoms might
not have volunteered for participation due to their perceived inability to complete functional tests.
Our study provides important preliminary information about associations between HRQoL and
objectively measured activity behaviors and physical function, and body composition in OCS.
Furthermore, this is the first study to provide a comprehensive cross-sectional analysis of selfreported PFD and its associations with HRQoL, objectively measured activity behavior, physical
function and body composition in OCS. Further strengths of our study include the relative
homogeneity of our sample of OCS in terms of disease and treatment stage and the inclusion of an
age-matched control group from the same community.

CONCLUSION
In this cross-sectional study advanced-stage OCS who had completed first-line treatment
had lower physical, but equivalent mental HRQoL, compared to controls. Ovarian cancer survivors
who reported better physical HRQoL did more MVPA/day, spent less time/day sedentary and had
better objective physical function. Pelvic floor dysfunction was not significantly different between
OCS and controls. Ovarian cancer survivors with more PFD had worse physical and mental
HRQoL, did less MVPA in ≥10-minute bouts, spent more time/day sedentary and had worse
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objective physical function. Post-treatment advanced-stage OCS have decreased physical HRQoL,
which is associated with modifiable factors such as PFD, MVPA, sedentary time and objective
physical function. This highlights the need for ongoing supportive care and the importance of
multidisciplinary interventions beyond the completion of first-line OC treatment.
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Cancer group
Control group

Physical Functioning (p = 0.024*)
70
60

Mental Health (p = 0.327)
57
53

Role Physical (p = 0.023*)

53

50

55
48

40

43
30
Role Emotional (p = 0.414)

56

54

20

49

54

Bodily Pain (p = 0.122)

47
51
57
Social Functioning (p = 0.096)

51

58

56

General Health (p = 0.021*)

Vitality (p = 0.056)

Figure 4. Median SF-36 subscale scores for Cancer and Control groups
*Statistical significance (p < 0.05)
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Table 5. Bladder, bowel and pelvic organ prolapse symptoms scores for Cancer and Control groups

Cancer group

Control group

p-value

(n = 20)

Median (Range)

(n = 20)

Median (Range)

T-test

Bladder score (/10)

1.11 (1.89)†

1.11 (0.00-4.00)

1.33 (1.61)†

1.33 (0.22-5.11)

0.989‡

Bowel score (/10)§

2.23±1.87

2.06 (0.00-6.18)

1.97±1.38

2.06 (0.00-4.41)

0.626

POP score (/10)§§

0.00 (0.00)†

0.00 (0.00-2.00)

0.00 (0.00)†

0.00 (0.00-4.67)

0.901‡

Pelvic Floor Score (/30)

4.05 (4.85)†

4.06 (0.00-8.71)

3.03 (2.66)†

3.03 (0.52-13.90)

0.624‡

Pelvic Floor Score (/30)¶

4.17±2.94

4.06 (0.00-8.71)

3.28±1.86

3.03 (0.52-7.83)

0.277

Sexually active

n (%)

n (%)

Yes

6 (30)

12 (60)

No

14 (70)

8 (40)

POP = Pelvic organ prolapse; Pelvic Floor Score = combined bladder, bowel and POP symptoms score for each participant
†Pearson Chi-square
Values are presented as mean±SD unless otherwise specified
†Median (interquar le range), ‡Mann-Whitney test
§Cancer group n = 19, §§Control group n = 19 due to missing data
¶Extreme outlier removed from Control group
*Statistical significance (p < 0.05)
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0.057†
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Chapter 5
CONCLUSION
OVERVIEW
This research aimed to provide a comprehensive profile of activity behaviors and
physiological characteristics of advanced-stage OCS who have completed first-line treatment. This
chapter is a summary of findings from the literature review (Chapter Two) and observational study
(Chapters Three and Four), while highlighting the strengths, challenges and clinical implications of
this work.
Chapter Two provides a summary of current literature relating to treatment-related sideeffects, concurrent comorbidities, body weight and composition, physical fitness and function, and
PA behavior of OCS. Findings from the literature review indicate that women diagnosed with OC
are faced with many challenges, such as persistent disease and treatment symptoms and side-effects,
concurrent comorbidities, obesity and physical inactivity. Overall, current literature is limited by a
lack of objectively measured data and the heterogeneous nature of existing OC studies.
Therefore, the primary aim of the observational study was to extend current literature by
assessing objectively measured activity behaviors (i.e., PA and sedentary behavior) and physical
function, body composition and musculoskeletal morphology of post-treatment advanced-stage
OCS compared to age-matched controls. Self-reported PFD and HRQoL of this sample of OCS
were also assessed. The results were that, compared to age-matched controls, OCS spent more time
in prolonged sedentary bouts, had lower cardiorespiratory fitness, upper body strength and physical
HRQoL, but had equivalent self-reported PFD. Further, better physical HRQoL was associated with
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more time spent doing MVPA, less time spent in sedentary behavior, better objective physical
function and less PFD. These findings suggest that many of the issues associated with reduced
physical HRQoL in post-treatment advanced-stage OCS are potentially modifiable with a
multidisciplinary approach that includes exercise oncology interventions.

LIMITATIONS, STRENGTHS AND IMPLICATIONS FOR
PRACTICE
The study design and modest sample size limit conclusions that can be drawn from this work.
Despite these limitations, the thesis provides important preliminary information about objectively
measured activity behaviors and physical function, body composition, musculoskeletal morphology,
self-reported PFD and HRQoL in post-treatment advanced-stage OCS. Conducting the
observational study provided challenges and insights worth considering in the development of
exercise intervention studies and exercise oncology guidelines.
Recruitment of participants for clinical research is known to be challenging and timeconsuming. In the current study there were several factors that impacted eligibility and recruitment.
A large percentage of OCS (20%) identified by clinicians as potentially eligible for the study could
not be reached, despite various attempts to contact them. Another 20% had recurrent disease at the
time of recruitment, or were too unwell to participate. A portion of eligible OCS (27%) declined the
invitation to participate due to lack of interest. Research in cancer populations indicates that clinical
trials are often considered an inconvenience to everyday life.1 Additionally, several eligible OCS
(14%) expressed interest to participate, but declined based on the fact that they lived far from the
location where assessments were conducted. This is consistent with previous research reporting
transportation issues and distance to trial sites as patient-related barriers to participation.1 Similar
challenges are likely to present when recruiting participants for exercise intervention studies and
need to be considered when developing strategies for recruitment of OCS into exercise intervention
studies.
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In the observational study, no adverse events were reported as result of functional and
strength testing. However, one repetition maximum (1-RM) strength testing was contra-indicated in
a small percentage of OCS (10% for 1-RM chest press, 10% for with 1-RM single leg extension)
with joint replacements or severe arthritis. In designing the study, a single leg extension 1-RM test
was selected as a conservative measure considering the possible high prevalence of PFD after OC
treatment. Based on our findings regarding the prevalence of PFD in OCS, a more functional
measure of lower body strength, such as the leg press, may be considered for OCS without
musculoskeletal and/or PFD contraindications. This work suggests that the majority of OCS can
safely undergo functional and strength testing, but that certain tests should be modified following
screening for comorbid conditions, PFD and treatment side-effects. This is likely to hold true for
exercise interventions, which may require an individualized approach based on participants’
treatment side-effects (e.g., peripheral neuropathy), comorbidities (e.g., arthritis, osteoporosis) and
current level of physical fitness and function. As such, comprehensive screening for the prevalence
and severity of persistent treatment side-effects and comorbidities, and exercise testing to determine
physical fitness and function, should precede exercise interventions.
This was the first study to assess PFD in OCS. However, only self-reported PFD was
assessed. Some objective measurement of PFD (e.g., ultrasound), as well as the inclusion of
questions regarding previous treatments for PFD and known risk factors for PFD (e.g., parity and
vaginal birth) would have provided a more complete picture of PFD for both OCS and controls.
This research suggests that OCS should undergo PFD screening to identify pelvic floor symptoms
that could necessitate an individualized approach to exercise testing and prescription.
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FUTURE RESEARCH
This thesis describes the activity behaviors, objective physiological characteristics, HRQoL
and self-reported PFD of post-treatment advanced-stage OCS. However, possible differences that
were not extensively investigated in our current study may exist based on the type of OC, treatment
stage and/or treatment regime. In this research study, differences were observed regarding some
activity behaviors and physiological characteristics based on type of treatment previously received.
This suggests that OCS on different treatment regimens may require different exercise intervention
strategies. Longitudinal studies incorporating larger sample sizes are needed to investigate potential
activity behavior and physiological differences between “sub-groups” of advanced-stage OCS (e.g.,
women with different types of OC and on different treatment regimens). Changes in activity
behavior, physiological characteristics and HRQoL of advanced-stage OCS over the entire disease
spectrum also need to be investigated. Furthermore, findings of this thesis suggest that the physical
HRQoL of post-treatment advanced-stage OCS are affected by potentially modifiable factors such
as insufficient MVPA and reduced objective physical function. Future pilot studies and randomized
controlled trials are needed to assess the feasibility and efficacy of tailored exercise interventions in
advanced-stage OCS who have completed first-line treatment.

CONCLUSION
In conclusion, this research examined activity behaviors and physiological characteristics of
post-treatment advanced-stage OCS to inform the design of supportive care interventions. Overall,
the findings of this research are that advanced-stage OCS who have completed first-line treatment
are insufficiently physically active and have decreased physical HRQoL, which is associated with
modifiable factors such as MVPA, sedentary time, objective physical function and PFD. Posttreatment OCS require ongoing multidisciplinary supportive care delivered by a team of allied
health professionals that includes exercise physiologists. Future exercise intervention studies are

80

required to investigate the feasibility and benefits of exercise as medicine for women who have
completed first-line treatment for advanced-stage OC.
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Appendix A – Detailed methods section
SETTING AND PARTICIPANTS
The study was conducted at the Exercise Medicine Research Institute at Edith Cowan
University and St John of God Subiaco Hospital in Perth, Western Australia. Ethical approval was
granted by the Edith Cowan University (Ref. No. 12511, 23/4/2015; Appendix B) and St John of
God Health Care Human Research Ethics Committees (Ref. No. 815, 12/6/2015; Appendix C). Two
groups of women were recruited: (1) ovarian cancer survivors (OCS) (n = 20) and (2) similarly
aged women with no previous cancer diagnosis (n = 20). We required 22 participants for each group
in order to achieve 80% statistical power at an alpha level of 0.05 (two-tailed) to detect a difference
in leg strength between groups. The power calculation was based on a publication in which a mean
difference in leg strength (1-RM leg press) of 22.5 kg, and a pooled variance of 25.5 kg (effect size
= 0.88) were reported between women with breast cancer and similarly aged women with no history
of cancer.1 Due to recruitment of OCS being slower than expected, we only managed to recruit 20
women in the allotted time frame.
Ovarian cancer survivors were eligible for participation if they had histologically confirmed
stage III – IV epithelial OC and were between 3 and 24 months post cancer-related treatment
(surgery and chemotherapy), were 18 years or older, able to obtain approval from their treating
oncologist or general practitioner, able to walk 400 meters, able to understand and speak English,
and had no existing or suspected bone metastasis, no acute illness or any musculoskeletal,
cardiovascular or neurological disorder that could put them at risk during exercise testing. The same
non-cancer eligibility criteria applied for the control group. Written informed consent was obtained
from all participants.
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DESIGN AND RECRUITMENT
We conducted a cross-sectional study. Participants for the OC group were recruited by
screening for potentially eligible participants in the rooms of three gynecological oncologists in
Perth. Potentially eligible OCS were informed of the research study either via a phone call from the
practice nurse or an information letter (Appendix D) and study brochure (Appendix E) sent out
from the oncologists’ rooms. The study coordinator (CS) then contacted potentially eligible
participants by phone to determine interest and confirm eligibility.
Participants for the control group were recruited by several methods. Initially participants
from the cancer group were asked if they had similarly aged female family members or friends who
would be willing to participate in the study. When required, control participants were recruited from
staff at the Edith Cowan University and a local cancer care center (Appendix F), and the wider
community. Interested women were asked to contact the study coordinator to confirm eligibility.
Women were recruited as control participants if they could be age-matched to an OC participant,
i.e., if they were of similar age, or no more than two years older or younger.
A study information pack containing a cover letter (Appendix G), participant information
letter (Appendix H and I), medical consent form (Appendix J and K), participant consent form
(Appendix L), demographic and health history questionnaire (Appendix M) and a Day 1 letter
(Appendix N) was posted to all interested and eligible participants. Follow-up telephone calls were
made one week after posting the study information packs to confirm receipt, answer questions
regarding the study and book assessments.

STUDY PROCEDURES
All participants underwent two separate assessments, no less than six, but no more than 14
days apart. Assessments took 2.5-3.0 hours and 1.5-2.0 hours respectively to complete and were
conducted at the Edith Cowan University Exercise Medicine Research Institute. All anthropometric,
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body composition and objective functional data were collected by the study coordinator, an
accredited exercise physiologist.
On commencement of the first assessment, consent forms, demographic and medical history
questionnaires, and study procedures were reviewed with participants. Participants were also
provided an opportunity to ask questions regarding the study. Anthropometric measures and resting
heart rate and blood pressure measures were completed. In addition, each participant underwent a
dual-energy X-ray absorptiometry (DXA) body composition and peripheral quantitative computed
tomography (pQCT) scan, and completed a series of functional measures for familiarization
purposes. At the end of the assessment, participants were provided with an ActiGraph (GT3X+)
accelerometer, an instruction sheet for accelerometer use (Appendix O), an activity monitor log
(Appendix P) and a second questionnaire assessing health-related quality of life (HRQoL), pelvic
floor dysfunction (PFD), physical activity (PA) level and PA motivation (Appendix Q).
To minimize the learning effect, all functional tests were repeated during the second
assessment. After completion of all tests on the second day, the study coordinator provided
feedback and exercise advice to interested participants.

OUTCOME MEASURES
Demographic and medical data were obtained by self-reported questionnaires and provided
information regarding participants’ age, marital status, educational attainment, employment status
and medical history. Additional information regarding date of cancer diagnosis, date of treatment
completion, cancer stage and treatment(s) received were acquired from OCS.

Anthropometric measures
Height (m) and body weight (kg), measured by digital measuring-and-weighing station
(Model 763, Seca, Hamburg, Germany), were used to calculate body mass index (BMI) in m/kg².
Waist and hip circumference (cm) were measured at the narrowest part of the torso or between the
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iliac crest and 12th rib, and the maximal circumference of the hip.2 Waist-to-hip ratio was
calculated by dividing waist circumference by hip circumference. For accurate set-up of the pQCT
scanner, left tibial length (with one exception due to a metal implant) was measured in cm from the
tibial plateau at the knee joint (proximal end) to the medial malleolus of the tibia (distal end). All
measures were recorded to the nearest 0.1.

Body composition
Whole-body DXA scans were performed using DXA (QDR-1500, Hologic Discovery A,
Waltham, MA, USA) to measure participants’ regional and whole-body lean and fat mass, as well
as bone mineral content (g) and areal bone mineral density (g/cm²). Dual-energy X-ray
absorptiometry has been established as a valid3, 4 and reliable5 measure of body composition and
has often been used to assess body composition or components thereof in a variety of cancer
populations.6-9
In addition to DXA scans, tibial peripheral quantitative computed tomography (pQCT) scans
(pQCT, XCT-3000; Stratec Medizintechnik, Pforzheim, Germany) were conducted. In contrast to
DXA, pQCT differentiates between trabecular and cortical bone and provides volumetric bone
mineral density values (in mg/cm³) of bone tissue at peripheral skeletal sites, thus providing more
comprehensive bone tissue information.10 Furthermore, while DXA measures fat and muscle mass,
pQCT provides information on the quality of muscle due to the ability to generate estimations of
muscle density.11 Four pQCT scan slices were measured at 4%, 14%, 38% and 66% of tibial length
respectively (distal to proximal). Variables across all tibial slices were retained for analysis.
Trabecular density and trabecular area were obtained from the 4% slice, cortical density and cortical
area were averaged across the 14% and 38% tibial slices, muscle density and muscle area were
obtained from the 66% slice, and tibial mass, total tibial area and tibial density were averaged
across the 4%, 14%, and 38% tibial slices.
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Physical activity and sedentary time
Objective PA and sedentary time were measured with a hip-worn tri-axial accelerometer
(ActiGraph GT3X+, ActiGraph Corp, FL, USA). Participants were asked to wear the accelerometer
continuously for seven days, except when bathing/showering or participating in water-based
activities. The GT3X+ was programmed to record raw data at a frequency of 30Hz, which were
later reduced to vertical axis movement counts/60 s epoch for the purpose of our analyses.
Accelerometer data were downloaded with Actilife (Version 6.13.3, ActiGraph Corp, FL, USA) and
processed in SAS (Version 9.3, SAS Institute Inc., NC, USA). An automated algorithm was used to
identify awake wear time12 and non-wear time.13 Non-wear time is defined as 90-minute periods of
zero acceleration counts/minute [cpm], with allowance for 2-min intervals of non-zero counts for
detection of accidental movement of the monitor, e.g., touching of monitor sitting on a table or
nightstand).13 To render days of data collection valid, a minimum awake wear time of 600 minutes
(10 hours) was required.14 A minimum of four valid days was required for analysis. Activity counts
were categorized as: sedentary (<100 cpm), light intensity PA (LIPA; 100-<1952 cpm), moderate
intensity PA (1952-<5275 cpm), vigorous intensity PA (≥5275 cpm), or moderate-to-vigorous PA
(MVPA; ≥1952 cpm).15,

16

Moderate-to-vigorous PA was assessed as total MVPA time/day and

MVPA time/day in strict ‘bouts’ of ten consecutive minutes or more with no interruption.
Participants were categorized as meeting (i.e., ≥150 minutes of MVPA/week) or not meeting (i.e.,
<150 minutes of MVPA/week) current PA guidelines for cancer survivors.17 Prolonged sedentary
bouts were defined as uninterrupted sedentary bouts of ≥30 minutes. Accelerometers are
increasingly being used to measure time spent, and patterns of accumulation, in different intensities
of physical activity and sedentary behavior.18-20
Self-reported physical activity was assessed by the Leisure Score Index (LSI) of the Godin
Leisure Time Exercise Questionnaire (GLTEQ). The questionnaire asks participants to recall their
average weekly frequency and duration of mild, moderate and strenuous activity during the past
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month. The GLTEQ is considered a valid and reliable measure of self-reported physical activity21
and is often utilized to assess physical activity behavior in gynecological cancer survivors.22, 23

Objective physical function
Objective physical function was assessed through a battery of tests including: (1) a series of
6-meter walking tasks, (2) 400-meter walking test, (3) repeated chair rise, and (4) muscular strength
tests. The study coordinator gave demonstrations of the 6-meter backwards walk, repeated chair rise
and strength tests and allowed sufficient rest periods between different tests as well as between
trials within a specific test. Participants were reminded that they could discontinue any test that
caused excessive discomfort or pain.
6-Meter walk tests – Three separate tests were conducted: (1) a usual pace walking test to
assess gait speed during daily activities, (2) a fast pace walking test to assess the fastest selfselected pace participants could safely walk at, and (3) a backwards walking test to assess dynamic
balance.23, 24 A 6-meter distance was marked with tape on the floor. Participants were instructed to
start walking from the 0-meter mark when ready and to continue walking past the 6-meter mark to
eliminate the effect of deceleration. For the backwards walk, participants were instructed to walk in
reverse on the 6-meter line following a toe-to-heel protocol. If participants lost balance and deviated
from the line, they were instructed to return to the line and continue walking. Time taken to
complete each task was measured by electronic timing gates (Swift Performance Equipment, NSW,
Australia) and the fastest of three trials for each 6-meter walking test was used for analysis. Both
the 6-meter walk test and the 6-meter backwards walk have been reported to have good test-retest
reliability.25-27
400-Meter walk test - Participants walked 400 meters by doing 10 laps of a 20-meter
course, marked with cones on the floor, in a long corridor. They were instructed to start on the
command “GO” after a “three-two-one” countdown, and to walk at the fastest pace they could
maintain over the total distance. Time taken to complete the 400-meter walk was measured by
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handheld stopwatch. The 400-meter walk test was developed as a practical alternative to maximal
or submaximal treadmill testing, to measure cardiorespiratory fitness in older adults.28 The test has
been reported as a valid measure of cardiorespiratory fitness28, 29 and mobility,30 with excellent testretest reliability (ICC = 0.95).29
Repeated chair rise – Participants were seated in a hard-backed chair (chair height = 46cm)
with their backs against the backrest and arms folded across their chests. They were instructed to
stand up to a fully upright position (knees fully extended) and to sit back down with upper backs
touching the back rest, as fast as they could safely do so five times. As with the 400-meter walk test,
participants were instructed to start on the command “GO” after a “three-two-one” countdown, and
time taken to complete the task was measured by handheld stopwatch. The fastest of three trials was
used for analysis. The repeated chair rise has been reported as a valid test for lower extremity
function31 with good test-retest reliability.25, 32
Muscular strength – One repetition maximum (1-RM) chest press and single leg extension
tests were used to measure dynamic upper and lower body muscular strength respectively. In
addition, isometric handgrip strength, reported to be a valid indicator of limb muscle strength,33 was
measured in all participants. All absolute strength values were divided by body weight to provide
information on relative strength.
One-RM testing is considered the “gold standard” of muscular strength testing34 and refers
to the maximal weight (in kg) an individual can move once with good technique through full range
of motion without compensatory movements. The 1-RM chest press was conducted on a Cybex
Smith machine (Cybex International, Medway, MA, USA) and a portable flat bench. The bar was
positioned at mid-sternal level and 90° elbow flexion for each participant. Lifts were only recorded
as successful if executed to full elbow extension. The 1-RM single leg extension was conducted on
a Cybex leg extension machine. The back rest and shin pad were adjusted after each participant was
seated to ensure that the knee joint was in line with the machine pivot point and at a 90° angle, and
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that the shin pad was positioned just above the ankle joint. Only movements executed to the same
degree of knee extension as during the warm-up were recorded as successful. Participants received
demonstrations and instructions concerning correct posture, breathing and movement execution
during both the familiarization and the follow-up sessions of 1-RM testing.
The 6-meter walking tasks, 400-meter walk and repeated chair rise were all conducted prior
to strength testing and served as general warm-up for 1-RM tests. Participants performed two
warm-up set of six and three repetitions respectively for each movement (chest press, right leg
extension and left leg extension, unless contraindicated). Subsequent attempts required single
movement executions at progressively heavier loads until the absolute 1-RM was determined. Rest
intervals between warm-up sets and 1-RM trials were two minutes. A maximal of three to five 1RM trials were attempted to avoid the effect of fatigue. One-RM testing, with one familiarization
session 4-8 days prior, has been reported to be a safe and reliable method of maximal strength
testing in older, untrained participants34 and has been utilized to measure muscular strength in a
variety of cancer populations.35-37
To measure handgrip strength participants were asked to stand upright whilst holding a
Jamar handgrip dynamometer (Lafayette, IN, USA) in their right hand, arm slightly away from the
body with approximately 20° elbow flexion, and to squeeze the dynamometer handle as forcefully
as possible. After a score was recorded, the test was repeated with the left hand. Three trials were
done for each hand, right and left alternatively, with a 30-second rest between each set of trials. The
highest score for the right hand was used for analysis. Good inter-tester38 and test-retest reliability39
has been established for handgrip dynamometry and, due to ease of application, the test is often
used for objective strength assessment in clinical populations, including different cancer
populations.40, 41
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Health-related Quality of Life
Health-related quality of life was measured using the Medical Outcomes Study Short Form36 (MOS SF-36) questionnaire.42 The SF-36 is a generic instrument that comprises eight subscales
measuring Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role-Emotional and Mental Health. Subscale scores were combined into a physical
component summary score (PCS) and a mental component summary score (MCS).43 All scores
were standardized to 1998 general US population norms so each scale is scored to have the same
average (50) and the same standard deviation (10). Higher scores reflect better HRQoL in the
domain being measured.44 The SF-36 has been established as a reliable and valid measure of quality
of life45 and is often used to assess quality of life of OCS.46

Pelvic Floor Dysfunction
Self-reported PFD was measured with the Australian Pelvic Floor Questionnaire (APFQ).47,
48

The APFQ has four subscales, with a range of questions each, to assess bladder, bowel and pelvic

organ prolapse (POP) symptoms and sexual function. Bladder, bowel and POP symptom scores out
of 10 were calculated. We did not calculate sexual function scores due to the large percentage of
women (55% of all participants) indicating sexual inactivity and thus not completing the section.
Bladder, bowel and POP symptom scores out of 10 were added for a combined bladder-bowel-POP
symptom score out of 30. Higher scores in all domains indicate that women are experiencing more
symptoms and thus more dysfunction. The APFQ has been indicated as valid and reliable measure
of all four pelvic floor domains.47, 48

STATISTICAL ANALYSIS
Data were analyzed using SPSS version 23 (IBM Corp., NY, USA). Variables were assessed
for normality using the Shapiro-Wilk test. Results for frequency data are presented as
number/percentage,

and

mean/standard

deviation
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for

normally

distributed

data,

or

median/interquartile range for non-normally distributed data. Non-normally distributed data were
analyzed using non-parametric tests. Probability of significant differences between OCS and control
participants were measured using the Pearson Chi square test, Likelihood Ratio or Fisher's exact test
for categorical data, and the independent t-tests or Mann-Whitney U tests for continuous variables.
One-way analysis of variance (ANOVA), Kruskal-Wallis and Bonferroni post hoc tests were used
to compare OCS treated with primary debulking surgery and adjuvant chemotherapy, OCS treated
with neoadjuvant chemotherapy and interval debulking surgery and control participants.
Association between variables for OCS was determined by Pearson r or Spearman rho correlations.
All tests were two-tailed, with statistical significance set at an alpha level of 0.05.
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Appendix D – Letter from oncologists
Date

Dear Mrs……..
Exercise needs in ovarian cancer survivors
The St John of God Gynaecologic Oncology research group is collaborating with
researchers at Edith Cowan University in a study which I would like to invite you to take
part in. The aim of this research study is to determine what types of exercise would be
most appropriate for women who have recently completed treatment for ovarian cancer.
Please find a brochure enclosed that provides further information about the research. Your
participation is entirely voluntary and you are not under any obligation to be involved.
Christelle Schofield, the chief study investigator, will contact you by telephone to see if you
are interested in being involved and to answer any questions that you may have.
Your participation in this would be most appreciated as it will help to improve our
understanding of cancers and treatments and thus to improve care for our patients.

Yours sincerely

(Dr’s Name)
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Appendix G – Cover letter
Date
Mrs………..
8 Any Street,
Suburb,
WA, 2122
Dear Mrs……..
Thank you for your interest in the research study, Physiological and disease specific
characteristics of ovarian cancer survivors.
Please find enclosed:
1. A participant information letter outlining all aspects of the study
2. A medical doctor consent form for your GP or specialist
3. An informed consent form for you
4. A demographic and health history questionnaire
5. Details of your first appointment
6. A parking permit for the Vario Clinic/Health and Wellness Institute parking area
Please read the participant information letter carefully. If you decide to participate
in the study:
1. Take the MEDICAL DOCTOR CONSENT FORM to your GP/specialist.
2. Following approval from your doctor to participate, please contact me to
arrange a meeting where an orientation to the study will be provided and
baseline measurements will commence.
3. Bring the medical doctor consent form, signed by your GP, with you on your first
assessment appointment. Everything else you will need on the first
appointment is outlined in the DAY 1 – ASSESSMENT sheet included in the
package.
4. I will contact you in a few days to confirm that you have received the
documents. However, if you have any questions in the meantime, please do not
hesitate to contact Christelle Schofield on 0459 900 264 or via e-mail at
c.schofield@ecu.edu.au.
Yours sincerely

Christelle Schofield
Accredited Exercise Physiologist
Masters Student – Edith Cowan University Health and Wellness Institute
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Appendix H – Information letter- cancer survivors

INFORMATION LETTER TO PARTICIPANTS – CANCER SURVIVORS

Physiological and disease specific characteristics of
ovarian cancer survivors
You are invited to participate in a research study because you have had a diagnosis of ovarian cancer.
This information letter explains the purpose and nature of the study and describes what will be
involved should you decide to participate. Please read the sheet carefully and do not hesitate to
contact the chief investigator if anything requires further clarification or if you have additional
questions or concerns. Please ensure that you do this before you sign the consent form to participate
in the study.
Contact persons
If you have any questions about the study, you can contact:
Mrs Christelle Schofield (Chief Investigator) - 0459 900 264
Prof Robert Newton (Principle Supervisor) - 08 6304 3443
Decision to participate
Your decision to participate in this study is voluntary. No explanation or justification is needed if you
choose not to participate. If you do decide to participate, you are free to withdraw your consent and
discontinue your involvement at any time during the study. A decision not to participate will not
disadvantage you or jeopardise your relationship with your care provider in any way. You will be
given a copy of the Consent Form to keep for your personal record.
The Participant Information Sheet explains the study and includes details such as:
o why this study might be suitable for you
o possible benefits and risks of study participation
o the type, frequency and risks of any testing that you will need to have as part of this study
o what your rights and responsibilities are if you agree to participate
What is the purpose of the study?
Women with ovarian cancer often experience a significant burden of disease and treatment sideeffects. Exercise has been acknowledged as a safe and effective supportive care intervention for
cancer survivors. Currently it is unknown what exercise is most appropriate for addressing the
disease specific and functional needs of women with ovarian cancer. The purpose of the study is to
measure physical function (i.e. walking speed, balance, muscle strength), body composition (i.e.
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how much muscle you have, your bone mineral density), physical activity participation and pelvic
floor function in ovarian cancer survivors. We plan to look at how these results relate to results
of similarly aged women who have not had cancer to better understand the specific exercise
needs of ovarian cancer survivors. Information obtained from this research will assist health
professionals to make exercise recommendations and to design the most appropriate exercise
programs for ovarian cancer survivors.

Am I eligible for participation?
As an ovarian cancer survivor to participate in the study you need to
 Be 18 years or older
 Have histologically confirmed stage III – IV ovarian cancer
 Not have cancer that has spread to the bone
 Not have undergone cancer-related surgery, chemotherapy and/or radiation therapy during
the last 3 months
 Not have completed your cancer-related treatment more than 24 months ago
 Not have an acute illness at the time of testing
 Not have any musculoskeletal, cardiovascular or neurological disorder that could put you at
risk during exercise testing, as determined by your specialist or general practitioner
What does participation in the study involve?
If you agree to participate in the study, you will be asked to
 Obtain consent from your specialist or general practitioner
 Invite a female friend, colleague or relative of similar age as yourself, who has never had a
diagnosis of cancer, to participate in the control group of this study. You are under no
obligation to do this, but if you know someone who would be willing and interested to
participate in the study, you can
o ask her to contact the chief investigator directly AND/OR
o give her the INFORMATION LETTER TO PARTICIPANTS – CONTROL GROUP included in your
package
 Complete standardized questionnaires
 Undergo a series of assessments at the Edith Cowan University in Joondalup to measure
different components of your physical fitness.
What questionnaires do I have to complete?
You will be asked to complete standardized questionnaires used to record demographic and
health history information as well as to assess quality of life, pelvic floor function, physical
activity level, physical activity motivation, and your thoughts on participating in the study. The
questionnaires can be completed in the privacy of your own home and are anticipated to take
you approximately half an hour.
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What do the assessments involve?
As study participant you will undergo the following series of assessments:


Body Composition & Bone Mineral Density
o Dual Energy X-Ray Absorptiometry (DEXA) scan will be used to assess whole body
composition (fat mass and lean mass) and bone mineral density of the hip and spine.
These assessments involve lying still on a specially designed platform for approximately
10 minutes while a scanning arm will move above your total body and above your hip and
spine (separate scans for your whole body, hip and spine). A low-dosage x-ray will pass
from the scanning arm to underneath the platform.
o Peripheral Quantitative Computed Tomography (pQCT) will be used to measure muscle
density and muscle cross-sectional areas of the lower limb. The assessment involves you
sitting in a chair with your leg extended and the circular scanning arm moving from your
ankle to your knee.

The total radiation dose for all scans undertaken during the study is very low, only a little more
than normal background radiation from an airplane flight and much less than, for example, an
international flight.


Physical Activity Level
You will be asked to wear an activity monitor (triaxial accelerometer) 24 hours a day for a 7day period in order to accurately measure your physical activity levels (i.e. how long you are
active for in a day). The device is very small (4.6cm x 3.3cm x 1.5cm), lightweight (19g) and
can be attached to your belt or worn around your waist using a strap.



Physical Function
A series of tests will be used to assess physical function. Before physical function tests are
performed, you will receive detailed instructions regarding all tests. Where necessary,
demonstrations, practice time and sufficient warm-up will be undertaken. All tests will be
supervised by the chief investigator, an accredited exercise physiologist, and your safety will
be observed at all times. These tests involve:
o
o
o
o

6-meter walk: You will be asked to walk 6 meters at your usual pace and at a fast pace
(i.e. as if you were running late for an appointment) (performed 3 times).
6-meter backwards walk: As a test of balance, you will be asked to walk backwards in a
toe-to-heel fashion for 6 meters (performed 3 times).
400-meter corridor walk: You will be asked to walk 20 meters in a corridor, turn around
and walk back to the starting position for a total of 10 times.
Chair rise: You will be seated in a hard-backed chair and asked to rise and sit 5
consecutive times, as fast as you can safely do so, without the use of your arms for
support (performed 3 times).
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o

Muscle strength: You will be asked to perform an upper and lower body one repetition
maximum test. During the one repetition maximum test you will be asked to lift
increasingly heavy weights on a chest press and leg extension weight-training machine
until you reach the most weight you can lift once using correct technique. In addition,
you will be asked to perform a hand-grip strength test, which entails squeezing a hand
dynamometer as hard as possible. Adequate rest will be provided in between tests to
avoid fatigue.

You will be asked to do these assessments on two separate occasions as outlined below, no
less than 6 but no more than 14 days apart. The purpose of the first testing session is to
familiarise you with all functional assessments in order to minimise any potential learning
effect. All testing will be conducted at the Edith Cowan University Health and Wellness
Institute in Joondalup (see map included) and will take approximately 2-3 hours.
OUTLINE OF TESTING SESSIONS
Session 1

Session 2 (6-14 days after Session 1)

The chief investigator will
The chief investigator will
 review consent forms, demographic and
 review quality of life, pelvic floor
health history questionnaire and study
function
and
physical
activity
procedures with you
questionnaires with you
 hand out quality of life, pelvic floor
 collect the activity monitor from you
function
and
physical
activity
 provide verbal feedback and an
questionnaires
(optional) exercise counselling to you
 provide you with an activity monitor
after conducting all tests
 measure your height and weight

You will undergo a DEXA and pQCT scan.
You will undergo functional testing:
 6-Meter walk test
o Usual pace forward
o Fast pace forward
o Toe-to-heel backward
 400-Meter walk test

You will undergo functional testing:
 6-Meter walk test
o Usual pace forward
o Fast pace forward
o Toe-to-heel backward
 400-Meter walk test

 Chair raise

 Chair raise

 Muscle strength testing
o One repetition
tests
o Grip strength test

 Muscle strength testing
o One repetition
tests
o Grip strength

maximum

How long will it take?
 2.5 hours for assessment
 30 minutes at home to complete
questionnaires

maximum

How long will it take?
 2 hours for assessment
 30 minutes for (optional) exercise
counselling
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What are the possible benefits of participating?
The direct benefit for you is that all study activities, including all assessments, are provided
at no cost to you. At the end of the second testing session the chief investigator will provide
feedback regarding your test results. You will then be offered the choice of either:




No exercise consultation, OR
A brief 30-minute exercise consultation with the chief investigator immediately after
the second testing session, OR
A more comprehensive 60-minute exercise consultation with the chief investigator
on another day at a time agreeable to both parties.

During the consultation of your choice the chief investigator will make exercise
recommendations based on your test results and answer any exercise related questions you
may have. Additionally, it is hoped that this study will contribute important new information
that will be useful in the management of ovarian cancers and long-term treatment side
effects.
What are the possible side effects and risks?
Prior to any testing, your specialist or GP will review your medical history and the study
protocols to make sure that it is safe for you to take part in the assessments involved in the
study. However, any strength and physical functional testing may result in mild discomfort
and muscle soreness. There is also the possibility of muscle pulls or strains, common to any
type of physical activity. Risk of falling may exist in the performance of some tasks. In order
to minimize these risks you will be thoroughly familiarized with the movements involved in
this investigation through comprehensive instructions and demonstrations, and supervised
at all times by the chief investigator, an accredited exercise physiologist. Furthermore,
during exercise testing it is possible to experience symptoms such as abnormal blood
pressure, fainting, light-headedness, nausea, and in very rare cases heart rhythm
disturbances or heart attack. These potential risks are common to any form of physical
activity. You will be asked to report any symptoms you experience during exercise testing
and your safety will be of primary importance at all times. In the event that an emergency
occurs, medical assistance will be obtained according to established emergency procedures
at the ECU Health and Wellness Institute.
DEXA and pQCT scans are routine clinical tests, but carry a small risk to you as they involve
exposure to radiation. The level of radiation exposure is exceedingly small (10-30
microSieverts [µSv]) in comparison to the natural annual radiation dose in western
communities (approximately 3000 µSv). A person would receive radiation exposure of
approximately 80 µSv on an airline flight of 8 hours or 30 to 40 µSv during a typical chest xray.
You may experience some discomfort in answering the items in the questionnaires. Your
responses will be kept strictly confidential. Some of the questions will ask about the level of
distress you are experiencing. If our study identifies that you are experiencing significant
distress you will be contacted and your permission will be sought to inform your GP or
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cancer specialist so that referral to appropriate services can be made. In addition, if you
should experience and express any distress at any stage during participation in the study,
the chief investigator will offer you the opportunity to contact a support person of your
choice (i.e. your husband or a friend). It is also recommended that you obtain permission
from your GP to be contacted if you feel you would rather contact him/her in case you
experience significant distress.
Privacy and confidentiality
The conduct of this research involves the collection, access and/or use of your identified
personal information. The information collected is confidential and will not be disclosed to
third parties without your consent, except to meet government, legal or other regulatory
authority requirements. A de-identified copy of this data may be used for other research
purposes. However, your anonymity will be safeguarded at all times. Participants will not be
referred to by name in research reports or during study discussions. If the results of the
study are published in a scientific journal, as is intended, no reader will be able to identify
individual patients. All records will be stored in a locked filing cabinet in a private office on
the Joondalup campus of Edith Cowan University with restricted access for a minimum of
five years. All computer records are restricted by password.
Are there any costs involved?
If you choose to participate in the study, you will be asked to attend two testing sessions at
ECU in Joondalup. Parking for visitors is available on campus at a cost of $1.50 per hour.
The parking permit included in the package will allow you access to the Health and Wellness
Institute’s parking area close to the building where you will undergo testing (indicated on
the included campus map). Please note that you still have to pay for parking and that tickets
can be purchased at vending machines located in the parking area. To help cover travel and
parking expenses, you will be provided with a $25.00 voucher at your second testing
session.
Will I receive any feedback?
You will receive verbal feedback regarding your test results at the end of the second testing
session. If you would like to discuss your results and ask questions about exercise, you have
the choice of either a brief 30-minute exercise consultation with the chief investigator
immediately after the second session or a more comprehensive 60-minute exercise
consultation on another day at a time agreeable to both parties. During the consultation of
your choice the chief investigator will make exercise recommendations based on your test
results and answer your exercise-related questions. A summary of study results will be made
available to all interested participants upon completion of the study.
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Contacting the investigators
We are happy to answer any questions you may have at this time. If you have any queries
later, please do not hesitate to contact either:
Mrs Christelle Schofield
Phone: 0459 900 264
E-mail: c.schofield@ecu.edu.au
Prof Robert Newton
Phone: (08) 6304 3443
E-mail: r.newton@ecu.edu.au
Independent Contact Person
The ECU Human Research Ethics Committee and the Human Research Ethics Committee at
St John of God Hospital, Subiaco have approved this project. If you have any concerns or
complaints about the research project and wish to talk to an independent person, you may
contact:
Research Ethics Officer
Edith Cowan University
270 Joondalup Drive
JOONDALUP WA 6027
Phone: (08) 6304 2170
Email: research.ethics@ecu.edu.au
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-ECU Health & Wellness Institute is located in building 21 on the Joondalup Campus of Edith
Cowan University.
-Please come to the Institute entrance located between building 21 and building 19 and
check in with reception.
-Parking is available for ECU Health & Wellness Institute clients directly behind building 19.
-Parking charges are $1.50/hour.
-If you have any problems locating the parking area please contact Christelle on 0459 900
264.
DIRECTIONS FROM THE FREEWAY:
• Take the Hodges Drive exit
• Turn Right onto Hodges Drive
• Turn right onto Joondalup Drive
• Turn left onto Lakeside Drive
• Turn left onto Chancellors Pass
• Turn left at the round-a-bout
• Take the first right into the Institute Client Car Park (to your right)
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Appendix I – Information letter- control
participants

INFORMATION LETTER TO PARTICIPANTS – CONTROL
GROUP

Physiological and disease specific characteristics of
ovarian cancer survivors
You are invited to participate in a research study because you have expressed an interest to
participate in the control group of an ovarian cancer study. This information sheet explains
the purpose and nature of the study and describes what will be involved should you decide
to participate. Please read the sheet carefully and do not hesitate to contact the chief
investigator if anything requires further clarification or if you have additional questions or
concerns. Please ensure that you do this before you sign the consent form to participate in
the study.
Contact persons
If you have any questions about the study, you can contact:
Mrs Christelle Schofield (Chief Investigator) - 0459 900 264
Prof Robert Newton (Principle Supervisor) - 08 6304 3443
Decision to participate
Your decision to participate in this study is voluntary. No explanation or justification is
needed if you choose not to participate. If you do decide to participate, you are free to
withdraw your consent and discontinue your involvement at any time during the study. A
decision not to participate will not disadvantage you or jeopardise your relationship with
your care provider in any way. You will be given a copy of the Consent Form to keep for your
personal record.
The Participant Information Sheet explains the study and includes details such as:
o why this study might be suitable for you
o possible benefits and risks of study participation
o the type, frequency and risks of any testing that you will need to have as part of this
study
o what your rights and responsibilities are if you agree to participate
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What is the purpose of the study?
Women with ovarian cancer often experience a significant burden of disease and
treatment side-effects. Exercise has been acknowledged as a safe and effective
supportive care intervention for cancer survivors. Currently it is unknown what exercise is
most appropriate for women with ovarian cancer to address their disease specific physical
functioning needs. The purpose of the study is to measure physical function (i.e. walking
speed, balance, muscle strength), body composition (i.e. how much muscle you have,
your bone mineral density), physical activity participation and pelvic floor function in
ovarian cancer survivors. We plan to look at how these results relate to results of similarly
aged women who have not had cancer to better understand the specific exercise needs of
ovarian cancer survivors. Information obtained from this research will assist health
professionals to make exercise recommendations and to design the most appropriate
exercise programs for ovarian cancer survivors.
Am I eligible for participation?
To participate in the partner/control group of the study you need to
 Be 18 years or older
 Never have had a diagnosis of cancer or history of cancer (other than non-melanoma
skin cancer)
 Not have an acute illness at the time of testing
 Not have any musculoskeletal, cardiovascular or neurological disorder that could put
you at risk during exercise testing, as determined by your specialist or general
practitioner
What does participation in the study involve?
If you agree to participate in the study, you will be asked to
 Obtain consent from your specialist or general practitioner
 Complete standardized questionnaires
 Undergo a series of assessments at the Edith Cowan University in Joondalup to
measure different components of your physical fitness.
What questionnaires do I have to complete?
You will be asked to complete standardized questionnaires used to record demographic
and health history information as well as to assess quality of life, pelvic floor function,
physical activity level, physical activity motivation, and your thoughts on participating in
the study. The questionnaires can be completed in the privacy of your own home and are
anticipated to take you approximately half an hour to complete.
What do the assessments involve?
As study participant you will undergo the following series of assessments:
 Body Composition & Bone Mineral Density
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o

o

Dual Energy X-Ray Absorptiometry (DEXA) scan will be used to assess whole
body composition (fat mass and lean mass) and bone mineral density of the
hip and spine. These assessments involve lying still on a specially designed
platform for approximately 10 minutes while a scanning arm will move above
your total body and above your hip and spine (separate scans for your whole
body, hip and spine). A low-dosage x-ray will pass from the scanning arm to
underneath the platform.
Peripheral Quantitative Computed Tomography (pQCT) will be used to
measure muscle density and muscle cross-sectional areas of the lower limb.
The assessment involves you sitting in a chair with your leg extended and the
circular scanning arm moving from your ankle to your knee.

The total radiation dose for all scans undertaken during the study is very low, only a
little more than normal background radiation from an airplane flight and much less
than, for example, an international flight.


Physical Activity Level
You will be asked to wear an activity monitor (triaxial accelerometer) for a 7-day
period in order to accurately measure your physical activity levels (i.e. how long you
are active for in a day). The device is very small (4.6cm x 3.3cm x 1.5cm), lightweight
(19g) and can be attached to your belt or worn around your waist using a strap.



Physical Function
A series of tests will be used to assess physical function. Before physical function
tests are performed, you will receive detailed instructions regarding all tests. Where
necessary, demonstrations, practice time and sufficient warm-up will be undertaken.
All tests will be supervised by the chief investigator, an accredited exercise
physiologist, and your safety will be observed at all times. These tests involve:
o

o
o
o

o

6-meter walk: You will be asked to walk 6 meters at your usual pace and at a
fast pace (i.e. as if you were running late for an appointment) (performed 3
times).
6-meter backwards walk: As a test of balance, you will be asked to walk
backwards in a toe-to-heel fashion for 6 meters (performed 3 times).
400-meter corridor walk: You will be asked to walk 20 meters in a corridor,
turn around and walk back to the starting position for a total of 10 times.
Chair rise: You will be seated in a hard-backed chair and asked to rise and sit 5
consecutive times, as fast as you can safely do so, without the use of your
arms for support (performed 3 times).
Muscle strength: You will be asked to perform an upper and lower body one
repetition maximum test. During the one repetition maximum test you will be
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asked to lift increasingly heavy weights on a chest press and leg extension
weight-training machine until you reach the most weight you can lift once
using correct technique. In addition, you will be asked to perform a hand-grip
strength test, which entails squeezing a hand dynamometer as hard as
possible. Adequate rest will be provided in between tests to avoid fatigue.
You will be asked to do these assessments twice in two testing sessions (outlined below)
no less than 6 but no more than 14 days apart. The purpose of the first testing session is
to familiarise you with all functional assessments in order to minimise any potential
learning effect. All testing will be conducted at the Edith Cowan University Health and
Wellness Institute in Joondalup (see map included) and will take approximately 2-3
hours.
OUTLINE OF TESTING SESSIONS
Session 1

Session 2 (6-14 days after Session 1)

The chief investigator will
The chief investigator will
 review consent forms, demographic
 review quality of life, pelvic floor
and health history questionnaire and
function
and
physical
activity
study procedures with you
questionnaires with you
 hand out quality of life, pelvic floor
 collect the activity monitor from you
function
and
physical
activity
 provide verbal feedback and (optional)
questionnaires
exercise counselling to you after
 provide you with an activity monitor
conducting all tests
 measure your height and weight

You will undergo a DEXA and pQCT scan.
You will undergo functional testing:
 6-Meter walk test
o Usual pace forward
o Fast pace forward
o Toe-to-heel backward
 400-Meter walk test
 Chair raise

You will undergo functional testing:
 6-Meter walk test
o Usual pace forward
o Fast pace forward
o Toe-to-heel backward
 400-Meter walk test
 Chair raise

 Muscle strength testing
 Muscle strength testing
o One repetition maximum
o One repetition maximum tests
tests
o Grip strength
o Grip strength test
o
How long will it take?
How long will it take?
 2.5 hours for assessment
 1 hours for assessment
 30 minutes at home to complete
 30 minutes for (optional) exercise
questionnaires
counselling
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What are the possible benefits of participating?
The direct benefit for you is that all study activities, including all assessments, are provided
at no cost to you. At the end of the second testing session the chief investigator will provide
feedback regarding your test results. You will then be offered the choice of either:
 No exercise consultation, OR



A brief 30-minute exercise consultation with the chief investigator immediately after
the second testing session, OR
A more comprehensive 60-minute exercise consultation with the chief investigator
on another day at a time agreeable to both parties.

During the consultation of your choice the chief investigator will make exercise
recommendations based on your test results and answer any exercise related questions you
may have. Additionally, it is hoped that this study will contribute important new information
that will be useful in the management of ovarian cancers and long-term treatment side
effects.
What are the possible side effects and risks?
Prior to any testing, your GP will review your medical history and the study protocols to
make sure that you are medically ready for the study procedures. However, any strength
and physical functional testing may result in mild discomfort and muscle soreness. There is
also the possibility of muscle pulls or strains, common to any type of physical activity. Risk of
falling may exist in the performance of some tasks. In order to minimize these risks you will
be thoroughly familiarized with the movements involved in this investigation through
comprehensive instructions and demonstrations, and supervised at all times by the chief
investigator, an accredited exercise physiologist. Furthermore, during exercise testing it is
possible to experience symptoms such as abnormal blood pressure, fainting, lightheadedness, nausea, and in very rare cases heart rhythm disturbances or heart attack.
These potential risks are common to any form of physical activity. You will be asked to
report any symptoms you experience during exercise testing and your safety will be of
primary importance at all times. In the event that an emergency occurs, medical assistance
will be obtained according to established emergency procedures at the ECU Health and
Wellness Institute.
DEXA and pQCT scans are routine clinical tests, but carry a small risk to you as they involve
exposure to radiation. The level of radiation exposure is exceedingly small (10-30
microSieverts [µSv]) in comparison to the natural annual radiation dose in western
communities (approximately 3000 µSv). A person would receive radiation exposure of
approximately 80 µSv on an airline flight of 8 hours or 30 to 40 µSv during a typical chest xray.
You may experience some discomfort in answering the items in the questionnaires. Your
responses will be kept strictly confidential. Some of the questions will ask about the level of
distress you are experiencing. If our study identifies that you are experiencing significant
distress you will be contacted and your permission will be sought to inform your GP or
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cancer specialist so that referral to appropriate services can be made. In addition, if you
should experience and express any distress at any stage during participation in the study,
the chief investigator will offer you the opportunity to contact a support person of your
choice (i.e. your husband or a friend). It is also recommended that you obtain permission
from your GP to be contacted if you feel you would rather contact him/her in case you
experience significant distress.
Privacy and confidentiality
The conduct of this research involves the collection, access and/or use of your identified
personal information. The information collected is confidential and will not be disclosed to
third parties without your consent, except to meet government, legal or other regulatory
authority requirements. A de-identified copy of this data may be used for other research
purposes.
However, your anonymity will be safeguarded at all times. Participants will not be referred
to by name in research reports or during study discussions. If the results of the study are
published in a scientific journal, as is intended, no reader will be able to identify individual
patients. All records will be stored in a locked filing cabinet in a private office on the
Joondalup campus of Edith Cowan University with restricted access for a minimum of five
years. All computer records are restricted by password.
Are there any costs involved?
If you choose to participate in the study, you will be asked to attend two testing sessions at
ECU in Joondalup. Parking for visitors is available on campus at a cost of $1.50 per hour.
The parking permit included in the package will allow you access to the Health and Wellness
Institute’s parking area close to the building where you will undergo testing (indicated on
the included campus map). Please note that you still have to pay for parking and that tickets
can be purchased at vending machines located in the parking area. To help cover travel and
parking expenses, you will be provided with a $25.00 voucher at your second testing
session.
Will I receive any feedback?
You will receive verbal feedback regarding your test results at the end of the second testing
session. If you would like to discuss your results and ask questions about exercise, you have
the choice of either a brief 30-minute exercise consultation with the chief investigator
immediately after the second session or a more comprehensive 60-minute exercise
consultation on another day at a time agreeable to both parties. During the consultation of
your choice the chief investigator will make exercise recommendations based on your test
results and answer your exercise-related questions. A summary of study results will be made
available to all interested participants upon completion of the study.
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Contacting the investigators
We are happy to answer any questions you may have at this time. If you have any queries
later, please do not hesitate to contact either:
Mrs Christelle Schofield
Phone: 0459 900 264
E-mail: c.schofield@ecu.edu.au
Prof Robert Newton
Phone: (08) 6304 3443
E-mail: r.newton@ecu.edu.au
Independent Contact Person
The ECU Human Research Ethics Committee and the Human Research Ethics Committee at
St John of God Hospital, Subiaco have approved this project. If you have any concerns or
complaints about the research project and wish to talk to an independent person, you may
contact:
Research Ethics Officer
Edith Cowan University
270 Joondalup Drive
JOONDALUP WA 6027
Phone: (08) 6304 2170
Email: research.ethics@ecu.edu.au
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ECU Health & Wellness Institute is located in building 21 on the Joondalup Campus of Edith
Cowan University.
• Please come to the Institute entrance located between building 21 and building 19 and
check in with reception.
• Parking is available for ECU Health & Wellness Institute clients directly behind building 19.
• Parking charges are $1.50 p/hour.
• If you have any problems locating the parking area please contact Christelle on 0459
900 264.
DIRECTIONS FROM THE FREEWAY:
• Take the Hodges Drive exit
• Turn Right onto Hodges Drive
• Turn right onto Joondalup Drive
• Turn left onto Lakeside Drive
• Turn left onto Chancellors Pass
• Turn left at the round-a-bout
• Take the first right into the Institute Client Car Park (will be to your right)
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Appendix J –Medical consent- cancer survivors

MEDICAL DOCTOR CONSENT FORM
Project Title: Physiological and disease specific characteristics of
ovarian cancer survivors
Researchers:
Mrs Christelle Scofield, Masters Student - E: c.schofield@ecu.edu.au - T: 0459 900 264
Prof Robert Newton, PhD - E: r.newton@ecu.edu.au - T: (08) 6304 5037
Dr Carolyn McIntyre, PhD - E: c.mcintyre@ecu.edu.au - T: (08) 6304 3987
Prof Daniel Galvão, PhD - E: d.galvao@ecu.edu.au - T: (08) 6304 3420
Institute: Edith Cowan University Health and Wellness Institute
St John of God, Subiaco
Dear Doctor,
The Edith Cowan University Health and Wellness Institute is undertaking a research study in
collaboration with The St John of God Gynaecologic Oncology research group investigating the
physiological and disease specific characteristics of ovarian cancer survivors. Women with
ovarian cancer often experience a significant burden of disease and treatment side-effects.
Exercise has been acknowledged as a safe and effective supportive care intervention for cancer
survivors. Currently it is unknown what exercise is most appropriate for women with ovarian
cancer to address their disease and treatment specific adverse side-effects. To better
understand their exercise needs and to design appropriate exercise interventions for both
research and clinical settings, we aim to identify unique physiological and disease specific
characteristics of women with ovarian cancer. The purpose of this study is to determine the
physiological and disease specific characteristics of ovarian cancer survivors and to explore
differences in physiological characteristics between women with ovarian cancer and similarly
aged women who have never been diagnosed with cancer.
Outcome measures in the study:
 Self-reported and objectively measured physical function. Objective physical function tests
include:
o muscle strength - measured by a 1-RM (repetition maximum) bench press and single
leg extension test, as well as by a handgrip strength test
o gait speed - measured by a 6-meter normal and fast pace walk
o dynamic balance - measured by a 6-meter backwards walk
o ability to get up from and sit back down in a chair – measured by a chair rise test
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o cardiorespiratory fitness and mobility – measured by a 400-meter walk (not on a
treadmill)
 Self-reported and objective (measured by an accelerometer) physical activity
 Body composition (total and trunk fat mass, lean mass, bone mineral density), muscle
density and bone strength – measured by DEXA and pQCT scans respectively
 Self-reported pelvic floor function
Information obtained from this research will assist health professionals in making exercise
recommendations and in designing the most appropriate exercise interventions for ovarian
cancer survivors.
As ovarian cancer survivors (cancer group) will be compared to similarly aged women who
have never been diagnosed with cancer (control group), two groups of 22 participants each
are required for the study. Your patient has expressed interest to participate in the cancer
group of the study.
Participants for the cancer group must meet all the following criteria:
 Histologically confirmed stage III – IV ovarian cancer
 No evidence or suspicion of bone metastasis
 Be 18 years or older
 Not have had cancer-related treatment during the last 3 months (e.g. surgery,
chemotherapy and/or radiation therapy)
 Not have completed cancer-related treatment more than 24 months ago
 No acute illness at the time of testing or any musculoskeletal, cardiovascular or
neurological disorder that could put the participant at risk of injury or illness during
exercise testing
The study has been approved by the Human Research Ethics Committees at Edith Cowan
University and St John of God Hospital, Subiaco and subjects will be free to withdraw from
the study at any time.
The concern of the researchers is of past and/or present medical conditions that may
compromise the individual’s ability to participate in the exercise testing involved with this
study, as described above. For these reasons all potential participants have been asked to
seek their medical doctor’s approval prior to involvement in the study.

_______________________ is in sufficient health to participate in this study.
Participant’s Name

_______________________
Doctors Name (please print)

______________________
Doctors Signature
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___________
Date

Please complete this letter and return it, along with any relevant records via facsimile to
Mrs Christelle Schofield on 08 9206 3807 at your earliest convenience, or by hand to the
participant.
If you would like to refer patients, or if you require more information, please feel free to
contact me or any of my supervisors. We will be happy to provide study outcomes to you as
per your request.
Yours sincerely

Christelle Schofield (AEP ESSAM)
Master of Science (Exercise Science) Student
Edith Cowan University Health and Wellness Institute
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Appendix K –Medical consent- control

MEDICAL DOCTOR CONSENT FORM
Project Title: Physiological and disease specific characteristics of
ovarian cancer survivors
Researchers:
Mrs Christelle Scofield, Masters Student - E: c.schofield@ecu.edu.au - T: 0459 900 264
Prof Robert Newton, PhD - E: r.newton@ecu.edu.au - T: (08) 6304 5037
Dr Carolyn McIntyre, PhD - E: c.mcintyre@ecu.edu.au - T: (08) 6304 3987
Prof Daniel Galvão, PhD - E: d.galvao@ecu.edu.au - T: (08) 6304 3420
Institute: Edith Cowan University Health and Wellness Institute
St John of God, Subiaco
Dear Doctor,
The Edith Cowan University Health and Wellness Institute is undertaking a research study in
collaboration with The St John of God Gynaecologic Oncology research group investigating
the physiological and disease specific characteristics of ovarian cancer survivors. Women
with ovarian cancer often experience a significant burden of disease and treatment sideeffects. Exercise has been acknowledged as a safe and effective supportive care intervention
for cancer survivors. Currently it is unknown what exercise is most appropriate for women
with ovarian cancer to address their disease and treatment specific adverse side-effects. To
better understand their exercise needs and to design appropriate exercise interventions for
both research and clinical settings, we aim to identify unique physiological and disease
specific characteristics of women with ovarian cancer. The purpose of this study is to
determine the physiological and disease specific characteristics of ovarian cancer survivors
and to explore differences in physiological characteristics between women with ovarian
cancer and similarly aged women who have never been diagnosed with cancer.
Outcome measures in the study:
 Self-reported and objectively measured physical function. Objective physical function
tests include:
o muscle strength - measured by a 1-RM (repetition maximum) bench press and
single leg extension test, as well as by a handgrip strength test
o gait speed - measured by a 6-meter normal and fast pace walk
o dynamic balance - measured by a 6-meter backwards walk
o ability to get up from and sit back down in a chair – measured by a chair rise test
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o cardiorespiratory fitness and mobility – measured by a 400-meter walk (not on a
treadmill)
 Self-reported and objective (measured by an accelerometer) physical activity
 Body composition (total and trunk fat mass, lean mass, bone mineral density), muscle
density and bone strength – measured by DEXA and pQCT scans respectively
 Self-reported pelvic floor function
Information obtained from this research will assist health professionals in making exercise
recommendations and in designing the most appropriate exercise interventions for ovarian
cancer survivors.
As ovarian cancer survivors (cancer group) will be compared to similarly aged women who have
never been diagnosed with cancer (control group), two groups of 22 participants each are
required for the study. Your patient has expressed interest to participate in the control group of
the study.
Participants for the control group must meet all the following criteria:
 Be 18 years or older
 Have never had a diagnosis of cancer or history of cancer (other than non-melanoma skin
cancer)
 Must not have an acute illness at the time of testing or any musculoskeletal, cardiovascular
or neurological disorder that could put the participant at risk of injury or illness during
exercise testing
The study has been approved by Human Research Ethics Committees at Edith Cowan University
and St John of God Hospital, Subiaco and subjects will be free to withdraw from the study at any
time.
The concern of the researchers are of past and/or present medical conditions that may
compromise the individual’s ability to participate in the exercise testing involved with this
study, as described above. For these reasons all potential participants have been asked to seek
their medical doctor’s approval prior to involvement in the study.

__________________ is in sufficient health to participate in this study.
Participant’s Name

_______________________
Doctors Name (please print)

______________________
Doctors Signature
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___________
Date

Please complete this letter and return it, along with any relevant records via facsimile to Mrs
Christelle Schofield on 08 9206 3807 at your earliest convenience, or by hand to the participant.
If you would like to refer patients, or if you require more information, please feel free to contact
me or any of my supervisors. We will be happy to provide study outcomes to you as per your
request.
Yours sincerely

Christelle Schofield (AEP ESSAM)
Master of Science (Exercise Science) Student
Edith Cowan University Health and Wellness Institute
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Appendix L – Participant consent form
PARTICIPANT CONSENT FORM
Physiological and disease specific characteristics of
ovarian cancer survivors
Participant Name:











I have read and understood the information letter and this participant consent form.
I understand that the study will be carried out as described in the information letter, a copy
of which I have retained.
I have obtained approval from my doctor to complete the activities required for participation
in the study.
The nature and possible effects of the study have been explained to me.
Any questions that I have asked have been answered to my satisfaction.
I understand that all research data will be treated as confidential.
I agree to participate in this study and give my consent freely.
I realise that my participation in this research study is voluntary and whether or not I decide
to participate is solely my decision.
I also realize that I can withdraw from the study at any time and that I do not have to give
any reasons for withdrawing.
I agree that research data gathered for the study may be published provided my name or
other identifying information is not disclosed.

Participant:

______________________

______________________

___________

Name

Signature

Date

Witness:

______________________

______________________

___________

Name

Signature

Date
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Appendix M – demographic information and health
history questionnaire
DEMOGRAPHIC INFORMATION
ID No: _________ Initials: _________
AND HEALTH HISTORY
Date:
QUESTIONNAIRE
__________________________

______________________________

_____________________________________

First Name

Last Name

Middle Initial

___________________

_________

_______________________

Date of Birth

Age

Sex

_______________________________________________________________________________
_______________________________________________________________________________
Postal Address

____________________ ____________________________ ____________________________
Home Phone

Mobile Phone

Email Address

_________________________________

________________________________________

Family Physician Name

Practice or Phone Number

_______________________ ____________________________ _________________________
Emergency Contact Name

Phone Number

Relationship

1. What is your current marital status?
Single

Married

Defacto

Separated

Divorced

Widowed

2. What is the highest level of education you have completed?
Primary

Secondary

Trade

Certificate/Diploma

Bachelor degree

Higher degree
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Other
______________________________________________________________________
3. What is your current level of employment (please circle)?
Retired

Unemployed

Casual

Part-time

Full time

Volunteer

If employed, what is your current occupation?
_______________________________________
If employed, how many hours/days do you work in a typical week?
____________ hours/day
____________ days/week
4. Are you or have you ever been a smoker?

Yes

No

If yes:
a. Are you a past or current smoker?
______________________________________
b. Age you started smoking:
_____________________________________________
c. Age you quit smoking (for past smokers only):
____________________________
d. Average number of cigarettes smoked per day:
___________________________

5. How many alcoholic drinks do you usually have per week?
_____________________________

6. Has your weight fluctuated more than a few kilos in the last 12 months?
Yes

No
a. If yes, has your weight gone up or down? __________________________
b. Approximately how many kilograms? ______________________________
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7. Do you experience shortness of breath while walking with others of your age?

Yes

No

8. Do you experience sudden tingling, numbness, or loss of feeling in arms, hands, legs, feet,
or face?
Yes
No
9. Do you experience swelling of your feet and ankles?

Yes

No

10. Do you get pains or cramps in your legs?

Yes

No

11. Do you experience any discomfort in your chest?

Yes

No

12. Have you ever been told that your blood pressure was abnormal?

Yes

No

If yes, do you currently take any medication (please provide details)?
________________________________________________________________________
________________________________________________________________________
13. Have you ever been told that your serum cholesterol or triglyceride level was high?
Yes

No

If yes, do you currently take any medication (please provide details)?
____________________________________________________________________________
____________________________________________________________________________

14. Have you ever been told that you have cardiovascular disease?

Yes

No

If yes, please provide details of condition and how it is controlled.
____________________________________________________________________________
____________________________________________________________________________

15. Have you ever been told that you have diabetes?

Yes

No

If yes, how is it controlled?
____________________________________________________________________________
____________________________________________________________________________
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16. Have you ever been told that you have osteoporosis?

Yes

No

If yes, how is it controlled?
____________________________________________________________________________
____________________________________________________________________________

17. Has a doctor or nurse ever told you that you had any of the following conditions?
Heart attack………………….. Yes

No

Stroke……………………… Yes

No

Emphysema………………….. Yes

No

Chronic bronchitis……. Yes

No

Arthritis………………………… Yes

No

Thyroid Disease……….. Yes

No

Peripheral Vascular..……… Yes
Disease

No

Angina..……………………. Yes
(chest pain)

No

If yes, please provide details
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________

18. When were you diagnosed with cancer?

Month: ________________ Year: ___________

19. What form of gynaecological cancer have you been diagnosed with?
_______________________________________________________________________________

20. Have you been diagnosed with a secondary cancer?
a.

Yes

No

If yes, what form?

___________________________________________________________________
b.

When?

___________________________________________________________________

21. Which types of treatment have you undertaken? (circle all that apply)
Surgery

Radiation

Chemotherapy
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Please indicate if you have received any other the type of treatment
_______________________________________________________________________________
22. Please specify the start date, duration and other important details of each treatment
Surgery (if applicable)
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
Chemotherapy (if applicable)
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
Radiation (if applicable)
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________

23. In addition to the above, do you have any other medical conditions (chronic or serious
illness)?

Yes

No

If yes, please provide details:
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
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24. Please list below the prescription medications you are currently taking. Fill out every
column for each medication you list.
Medication

Duration
(in years and months)

26. Have you ever had any surgery (unrelated to cancer)

Reason for taking (i.e. which
medical condition) and other
comments

Yes

No

If yes, please provide details about the type, date and reason for the surgery
Type of Surgery

Date of Surgery
(month & year)

Reason for Surgery & details of any
continuing impairments
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Appendix N – Day 1 letter
DAY 1 – ASSESSMENT
Appointment Details
Date:

Please call Christelle Schofield on 0459 900 264 to arrange an assessment
date at your convenience after you have received permission from your
doctor to take part in the study.

Venue:

Edith Cowan University, Health and Wellness Institute
Level 2, Building 21
270 Joondalup Drive
Joondalup, WA, 6027

Parking:

Visitor Car Parking is available in Car Park 13 next to the Health and
Wellness Institute at $1.50 per hour. (Enter off Lakeside Drive). Please
display your purchased parking ticket as well as the parking permit included
in this package on your vehicle’s dashboard.

It would be advisable to remove all jewellery and wear loose, unrestrictive clothing and
training shoes to both assessment sessions if possible.

Things to remember:
 Please eat your breakfast and take any medications as usual.
 Please bring
o change for parking
o the signed letter from your specialist/GP
o your signed consent form
o the completed Demographic and Health History Questionnaire
 If you use a hearing aid or glasses, please ensure you have them with you on the
day.
 Wear clothing and footwear suitable for exercise.
The DAY 1 schedule will involve:
 Information about the study and time for asking questions
 Review of questionnaires (please bring your reading glasses)
 DEXA and PQCT scans of your bone density and body composition
 Tests of your physical performance
If a problem arises on the day (for example you are running late or get lost), please
contact Christelle on 0459 900 264.
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Appendix O - Activity monitor instructions
ACTIVITY MONITOR INSTRUCTIONS
The activity monitor measures the amount of physical activity you do in your
everyday life. It is also used to measure the amount and quality of your sleep.

1. Please start wearing the monitor from:
_________________________________________________
2. Please take off the monitor:
_________________________________________________
If you have any questions about the activity monitor please call the chief study
investigator, Christelle Schofield, on 0459 900 264.
If there is no answer, please leave a message. Your call will be responded to as
soon as possible.
Where do I wear the activity monitor?
o The monitor needs to be worn at the hip area of your waist with the
black button facing the top (Do not twist the button).
o The monitor can be worn either above or beneath clothing, and it is not
necessary for it to make contact with the skin.
o The monitor must be held snugly against the body to work properly (i.e. must
be secure and not bounce or slide when you’re moving).
 How long do I wear the activity monitor for?
o We ask that you wear the monitor for a period of 7 days.
o To get the most accurate information, it is very important to wear the
monitor 24 hours a day if possible.
o This includes when you are asleep at night.
o The monitor should be taken off to bath/shower.
o You need to take off the activity monitor on the date and time listed
above.
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 What happens if I get the activity monitor wet?
o It’s preferable if the monitor doesn’t get wet, but it is water resistant and
will not be affected by getting slightly wet.
o If you are a swimmer please take the device off before getting into the
pool/ocean.
o Note the device is water resistant and not water proof.
 How do I return the monitor?
o If you complete the 7-day period before your second assessment, please
bring the monitor with you when you return to the ECU Health and
Wellness Institute for your second assessment.
o If you complete the 7-day period after your second assessment you will
be provided with a prepaid envelope to post the monitor back to the
Institute via any red Australia Post mailbox.
o If you choose to withdraw from the study after the first assessment and
after you have received the monitor, Christelle will contact you to make
arrangements for the monitor to be returned to the Institute.
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Appendix P - Activity monitor log
ACTIVITY MONITOR LOG
Study ID: __________
Date: ____/____/____
Please use this form to document any time that you didn’t wear the monitor during the 7day period, or any issues you had wearing the monitor.

DETAILS
Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7
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Appendix Q - Questionnaires

QUESTIONNAIRES
Name: ______________________________________ Date: ___________________

 Please take your time completing these important questionnaires and answer all
questions as honestly as you can. Please note that there are questions on both
sides of each page in this package.

 Your responses provide extremely valuable information regarding the impact of
cancer and cancer-related treatment on cancer survivors and have the potential to
influence the information and services provided to all cancer survivors and
specifically ovarian cancer survivors worldwide.

 We really appreciate your time and value the contribution you are making to
advancing the scientific knowledge surrounding the exercise needs of ovarian
cancer survivors.

 If you have any questions whatsoever don’t hesitate to contact:
Christelle Schofield
Chief Study Investigator
Phone: 0459 900 264
E-mail: c.schofield@ecu.edu.au
 Please return the questionnaires to Christelle on your next testing session.

THANK YOU!
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YOUR HEALTH AND WELL-BEING
This questionnaire asks for your views about your health. This information will help keep track of
how you feel and how well you are able to do your usual activities. For each of the following
questions, please circle the one number that best describes your answer.
1. In general, would you say your current health is:
Excellent

Very Good

Good

Fair

Poor

1

2

3

4

5

2. Compared to one year ago, how would you rate your health in general now?
Much better
now than one
year ago
1

Somewhat
better now than
one year ago
2

About the same
as one year ago
3

Somewhat
worse now than
one year ago
4

Much worse
now than one
year ago
5

3. The following questions are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much?
Yes,
limited
a lot
a) Vigorous activities, such as running, lifting heavy

Yes,
limited
a little

No, not
limited
at all

1

2

3

1

2

3

c) Lifting or carrying groceries.

1

2

3

d) Climbing several flights of stairs.

1

2

3

e) Climbing one flight of stairs.

1

2

3

f) Bending, kneeling, or stooping.

1

2

3

g) Walking more than a mile.

1

2

3

h) Walking several hundred yards.

1

2

3

i) Walking one hundred yards.

1

2

3

j) Bathing or dressing yourself

1

2

3

objects, participating in strenuous sports.
b) Moderate activities, such as moving a table, pushing
a vacuum cleaner, bowling, or playing golf.
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4. During the past 4 weeks, how much of the time have you had any of the following problems
with your work or other regular daily activities as a result of your physical health?
All of
the
time
a) Cut down on the amount of time you spent
on work or other activities.
b) Accomplished less than you would like.
c) Were limited in the kind of work or other
activities.
d) Had difficulty performing the work or other
activities (for example, it took extra effort).

Most
of the
time

Some
of the
time

A little
of the
time

None
of the
time

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

5. During the past 4 weeks, how much of the time have you had any of the following problems
with your work or other regular daily activities as a result of any emotional problems (such as
feeling depressed or anxious)?
All of
the
time
a) Cut down on the amount of time you
spent on work or other activities.
b) Accomplished less than you would like.
c) Did work or other activities less carefully
than usual.

Most of Some
the
of the
time
time

A little
of the
time

None
of the
time

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

6. During the past 4 weeks, to what extent has your physical health or emotional problems
interfered with your normal social activities with family, friends, neighbours, or groups?
Not at all

Slightly

Moderately

Quite a bit

Extremely

1

2

3

4

5
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7. How much bodily pain have you had during the past 4 weeks?
None

Very mild

Mild

Moderate

Severe

Very severe

1

2

3

4

5

6

8. During the past 4 weeks, how much did pain interfere with your normal work (including both
work outside the home and housework)?
Not at all

A little bit

Moderately

Quite a bit

Extremely

1

2

3

4

5

9. These questions are about how you feel and how things have been with you during the past 4
weeks. For each question, please give the one answer that comes closest to the way you have
been feeling. How much of the time during the past 4 weeks…

a) Did you feel full of life?
b) Have you been very nervous?

All of
the
time
1

Most of Some
the
of the
time
time
2
3

A little
of the
time
4

None
of the
time
5

1

2

3

4

5

1

2

3

4

5

d) Have you felt calm and peaceful?

1

2

3

4

5

e) Did you have a lot of energy?

1

2

3

4

5

1

2

3

4

5

g) Did you feel worn out?

1

2

3

4

5

h) Have you been happy?

1

2

3

4

5

i) Did you feel tired?

1

2

3

4

5

c) Have you felt so down in the dumps that
nothing could cheer you up?

f) Have you felt downhearted and
depressed?
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10. During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting friends, relatives, etc.)?
All of the time

Most of the time

Some of the
time

A little of the
time

None of the time

1

2

3

4

5

11. How TRUE or FALSE is each of the following statements for you?
Definitely
true
a) I seem to get sick a little easier

Mostly
true

Don't
know

Mostly
false

Definitely
false

1

2

3

4

5

b) I am as healthy as anybody I know.

1

2

3

4

5

c) I expect my health to get worse.

1

2

3

4

5

d) My health is excellent.

1

2

3

4

5

than other people.
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PHYSICAL ACTIVITY LEVEL
For this next question, we would like you to recall your average weekly exercise in the PAST
MONTH.
When answering these questions please:
 Only count exercise sessions that lasted 10 minutes or longer in duration.

1.



Only count exercise that was done during free time (i.e., not occupation or housework).



Note that the main difference between the three categories is the intensity of the
exercise.

Considering a typical week (7 days) how many times on the average did you do the following
kinds of exercise in the PAST MONTH?

Average Frequency

Average Duration

a. STRENUOUS EXERCISE
(HEART BEATS RAPIDLY, SWEATING)
(e.g. running, aerobics classes,
vigorous swimming, vigorous bicycling).

________times/week

_______ minutes

b. MODERATE EXERCISE
(NOT EXHAUSTING, LIGHT PERSPIRATION)
(e.g. fast walking, tennis, easy bicycling,
easy swimming, popular and folk dancing).

_______ times/week

_______ minutes

c. MILD EXERCISE
________ times/week
(MINIMAL EFFORT, NO PERSPIRATION)
(e.g. easy walking, yoga, lawn bowling,).
d. RESISTANCE EXERCISE
(e.g., repetitively lifting weights using
your own body weight, dumbbells, weight
machines, or resistance bands)

_______ minutes

________ times/week

_______ minutes

2. During a typical 7-Day period (a week), in your leisure time, how often do you engage in any
regular activity long enough to work up a sweat (heart beats rapidly)?
Often

Sometimes

Never/Rarely

1

2

3
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PELVIC FLOOR FUNCTION
For each of the following questions, please circle the one number that best describes your
answer.
Consider your experiences during the last month.
Bladder function
1. How many times do you pass urine in the day?

Up to 7

between 8 and 10

between 11 and 15

more than 15

0

1

2

3

2. How many times do you get up at night to pass urine?

0-1

2

3

More than 3

0

1

2

3

frequently (once or
more per week)
2

always (every night)

3. Do you wet the bed before you wake up at night?
never
0

occasionally (less than
once per week)
1

3

4. Do you need to rush or hurry to pass urine when you get the urge?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

5. Does urine leak when you rush or hurry to the toilet or can’t you make it in time?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

6. Do you leak urine with coughing, sneezing, laughing or exercising?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2
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daily
3

7. Is your urinary stream (urine flow) weak, prolonged or slow?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

8. Do you have a feeling of incomplete bladder emptying?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

9. Do you need to strain to empty your bladder?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

10. Do you have to wear pads because of urinary leakage?

never

As a precaution

0

1

When exercising
/during a cold
2

daily
3

11. Do you limit your fluid intake to decrease urinary leakage?

never

before going out

moderately

always

0

1

2

3

more than 1 per
month
3

12. Do you have frequent bladder infections?

no

1-3 per year

4-12 per year

0

1

2

13. Do you have pain in your bladder or urethra when you empty your bladder?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2
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daily
3

14. Does urine leakage affect your routine activities like recreation, socialising, sleeping, shopping etc.?
not at all

slightly

moderately

greatly

0

1

2

3

15. How much does your bladder problem bother you?
not at all

slightly

moderately

greatly

0

1

2

3

less than once per
week
2

more than once per
day
3

Bowel function
16. How often do you usually open your bowels?
every other day or
daily
0

less than every 3 days
1

17. How is the consistency of your usual stool?
soft, firm or hard (pebbles)

variable

watery

0

1

2

18. Do you have to strain a lot to empty your bowels?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

19. Do you use laxatives to empty your bowels?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

20. Do you feel constipated?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2
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daily
3

21. When you get wind or flatus, can you control it or does wind leak?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

22. Do you get an overwhelming sense of urgency to empty your bowels?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

23. Do you leak watery stool when you don’t mean to?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

24. Do you leak normal stool when you don’t mean to?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

25. Do you have a feeling of incomplete bowel emptying?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

26. Do you have to use finger pressure to help empty your bowels?
never
0

occasionally (less than
once per week)
1

frequently (once or
more per week)
2

daily
3

27. How much does your bowel problem bother you?
not at all

slightly

moderately

greatly

0

1

2

3
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Prolapse symptoms
28. Do you have a sensation of tissue protrusion or a lump or bulging in your vagina?
never

occasionally (less than
once per week)
1

0

frequently (once or
more per week)
2

daily
3

29. Do you experience vaginal pressure or heaviness or a dragging sensation?
never

occasionally (less than
once per week)
1

0

frequently (once or
more per week)
2

daily
3

30. Do you have to push back your prolapse in order to void?
never

occasionally (less than
once per week)
1

0

frequently (once or
more per week)
2

daily
3

31. Do you have to push back your prolapse to empty your bowels?
never

occasionally (less than
once per week)
1

0

frequently (once or
more per week)
2

daily
3

32. How much does your prolapse bother you?
not at all

slightly

moderately

greatly

0

1

2

3

Sexual function
33. Are you sexually active? (please tick the box relevant to you)
no
less than once per week
once or more per week
daily or most days

If you are not sexually active, please continue to answer questions 34 and 42 only
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34. If you are not sexually active, please tell us why: (please tick the box relevant to you)
I do not have a partner
I am not interested
my partner is unable
vaginal dryness
too painful
embarrassment due to the prolapse or incontinence
other reasons: _________________________________________

35. Do you have sufficient natural vaginal lubrication during intercourse?
yes
0

no
1

36. During intercourse vaginal sensation is:
normal/pleasant

minimal

painful

none

0

1

1

3

37. Do you feel that your vagina is too loose or lax?
never

occasionally

frequently

always

0

1

2

3

38. Do you feel that your vagina is too tight?
never

occasionally

frequently

always

0

1

2

3

39. Do you experience pain with sexual intercourse?
never

occasionally

frequently

always

0

1

2

3
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40. Where does the pain during intercourse occur?
Not applicable, I do
not have pain
0

at the entrance to the
vagina
1

deep inside, in the
pelvis
2

both at the entrance
and in the pelvis
3

41. Do you leak urine during sexual intercourse?
never

occasionally

frequently

always

0

1

2

3

42. How much do these sexual issues bother you?
not applicable, I do not have problems
not at all

slightly

moderately

greatly

0

1

2

3

Baessler K., O’Neill S.M., Maher C.F., Battistutta D. (2010) A validated self-administered female pelvic floor
questionnaire. Int Urogynecol J 21: 163-172
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YOUR FEELING ABOUT EXERCISE
The following questions ask you to rate how you feel about exercising on your own over the next
month. Please note that this study is not an exercise intervention study. However, the
information you provide regarding your feelings about exercise will be extremely useful in the
design and implementation of exercise intervention programs for women with ovarian cancer.
Exercise, for the purpose of the questionnaire, is defined as planned, structured and repetitive
activity with the purpose to improve or maintain physical fitness and health. It excludes
occupational, household and leisure activities. Ideally an exercise program should consist of:
 2 strength or resistance training sessions/week using for instance your own body weight,
weight machines, resistance bands or dumbbells.


150 minutes of moderate intensity aerobic-type exercise/week, for instance brisk
walking, cycling, swimming or tennis.



Stretching exercises for mobility.

Please pay careful attention to the words and descriptors at the end of each scale and circle the
number that best represents how you feel. Please answer all items from (a) to (f).
I think that doing exercise over the next month would be:
(a)
1
Extremely
Useless

2
Quite
Useless

3
Slightly
Useless

4
Neutral

5
Slightly
Useful

6
Quite Useful

7
Extremely
Useful

4
Neutral

5
Slightly
Enjoyable

6
Quite
Enjoyable

7
Extremely
Enjoyable

(b)
1
2
3
Extremely
Quite
Slightly
Unenjoyable Unenjoyable Unenjoyable
(c)
1
Extremely
Harmful

2
Quite
Harmful

3
Slightly
Harmful

4
Neutral

5
Slightly
Beneficial

6
Quite
Beneficial

7
Extremely
Beneficial

2
Quite
Painful

3
Slightly
Painful

4
Neutral

5
Slightly
Beneficial

6
Quite
Beneficial

7
Extremely
Beneficial

(d)
1
Extremely
Painful
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(e)
1
Extremely
Unimportant

2
Quite
Unimportant

3
Slightly
Unimportant

4
Neutral

5
Slightly
Important

6
Quite
Important

7
Extremely
Important

2
Quite
Boring

3
Slightly
Boring

4
Neutral

5
Slightly
Fun

6
Quite
Fun

7
Extremely
Fun

(f)
1
Extremely
Boring

This next set of questions asks you to rate how other people in your life may feel about you doing
exercise over the next month. Please pay careful attention to the words and descriptors at the
end of each scale and circle the number that best represents how they might feel. Please answer
all items from (a) to (c).
I think that if I do exercise over the next month, most people who are important to me would
be:
(a)
1
Extremely
disapproving

2
Quite
disapproving

3
Slightly
disapproving

4
Neutral

5
Slightly
approving

6
Quite
approving

7
Extremely
approving

2
Quite
discouraging

3
Slightly
discouraging

4
Neutral

5
Slightly
encouraging

6
Quite
encouraging

7
Extremely
encouraging

2
Quite
unsupportive

3
Slightly
unsupportive

4
Neutral

5
Slightly
supportive

6
Quite
supportive

7
Extremely
supportive

(b)
1
Extremely
discouraging
(c)
1
Extremely
unsupportive

This next question asks you to rate how active (how much exercise) you think other people in
your life are likely to do over the next month.
I think that over the next month, most people who are important to me will themselves be:
(a)
1
Extremely
inactive

2
Quite
inactive

3
Slightly
inactive

4
Neutral

5
Slightly
active

6
Quite
active

7
Extremely
active

This next set of questions asks you to rate how motivated you are to do exercise training over the
next month. Pay careful attention to the words at the end of each scale and circle the number
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that best represents your level of motivation.
(a) How motivated are you to do exercise over the next month?

1
Extremely
unmotivated

2
Quite
unmotivated

3
Slightly
unmotivated

4
Neutral

5
Slightly
motivated

6
Quite
motivated

7
Extremely
motivated

(b) I strongly intend to do everything I can to do exercise over the next month.

1
Strongly
disagree

2
Moderately
disagree

3
Slightly
disagree

4
Neutral

5
Slightly
agree

6
Moderately
agree

7
Strongly
agree

6
Quite
committed

7
Extremely
committed

(c) How committed are you to doing exercise over the next month?

1
2
3
Extremely
Quite
Slightly
uncommitted uncommitted uncommitted

4
Neutral

5
Slightly
committed

These next questions ask you to rate how likely you feel it is that you will be able to do exercise
over the next month if you were really motivated. Pay careful attention to the words at the end
of each scale and circle the number that best represents how you feel.
If you were really motivated…
(a) How controllable would it be for you to do exercise training over the next month?

1
2
3
4
Extremely
Quite
Slightly
Neutral
uncontrollable uncontrollable uncontrollable

5
Slightly
controllable

6
Quite
controllable

7
Extremely
controllable

(b) How confident would you be that you could do exercise over the next month?

1
Extremely
unconfident

2
Quite
unconfident

3
Slightly
unconfident

4
Neutral
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5
Slightly
confident

6
Quite
confident

7
Extremely
confident

(c) Do you feel that whether or not you do exercise over the next month would be completely
up to you?

1
Strongly
disagree

2
Moderately
disagree

3
Slightly
disagree

4
Neutral

5
Slightly
agree

6
Moderately
agree

7
Strongly
agree

(d) How easy or difficult would it be for you to do exercise training over the next month?

1
Extremely
difficult

2
Quite
difficult

3
Slightly
difficult

4
Neutral

5
Slightly
easy

6
Quite
easy

7
Extremely
easy

(e) Do you feel you would have complete control over whether or not you do exercise over
the next month?

1
Strongly
disagree

2
Moderately
disagree

3
Slightly
disagree

4
Neutral

5
Slightly
agree

6
Moderately
agree

7
Strongly
agree

(f) How certain or uncertain would you be that you could do exercise over the next month?

1
Extremely
uncertain

2
Quite
uncertain

3
Slightly
uncertain

4
Neutral

5
Slightly
certain

6
Quite
certain

7
Extremely
certain

Do you have a specific plan for where, when, and how you are going to exercise over the next
month?
1
Not at all

2
A little bit

3
Somewhat
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4
Quite a bit

5
Very much

END OF QUESTIONNAIRE PACK
Thank you very much for your time and contribution to
this important research!
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Appendix R – Data collection Sheet
ID No: _____________ Initials: __________

DATA COLLECTION SHEET

1.

Informed Consent
History

Date: ___________________
Familiarization
Baseline
Assessor:

GP Consent

Demographic Info & Health

2. Medical History: (conditions that may impact function/require tests to be modified)
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
3. Body Composition:
Height: _____________cm Weight: ______________kg

BMI: ___________ (kg/m2)

4. Circumferences: Min of 2 trials with the 3rd trial necessary if a 2mm difference between trials
Waist: ____________cm

____________cm

____________cm

Hip:

____________cm

____________cm

_____________cm

5. DEXA full body scan: remove shoes, socks, ALL metal (jewellery, underwire bra) and any
prosthetics
Completed

PQCT scan:

Tibia Length (left): ________________

Completed

6. Resting Blood Pressure & HR: (taken after resting in a supine position for 5 minutes)Blood
Pressure: _____________mmHg

_____________mmHg

_____________mmHg

Heart Rate: _____________bpm

_____________bpm

_____________bpm

7. 6m Walk Tests:
Normal:

_______sec

_______sec

_______sec

BEST: _______sec

Fast:

_______sec

_______sec

_______sec

BEST: _______sec

Backwards: _______sec

_______sec

_______sec

BEST: _______sec
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8. 400 meter Walk:
Heart rate: Before test: _______ bpm
1 minute after: _______ bpm

Immediately after:

_______ bpm

2 minutes after:

_______ bpm

Warm-up Lap (“walk from 1 marker to the other in as few strides as possible”)
Number of strides: (for initial 20 meters) _______
Laps: 1

2

3

4

5

6

7

8

9

10

400m Walk Time: ______________

9. Repeated Chair Rise: 2min rest between trials
Trial 1: _________sec

Trial 2: _________sec

Trial 3: _________sec BEST: _________sec

10. Strength Testing
a. 1 RM horizontal Chest Press:
Bar Start: _________________

Pillow Used: _______________

Bench Position: ____________cm

Step Height: _______________

Grip Distance: _____________cm
Warm-up:

6 x 60% 1RM = ________kg (2min)

1RM Attempts:

3 x 80% 1RM = ________kg (2min)

Trial 1: __________kg (2min)

Trial 2: __________kg (2min)

Trial 3: __________kg (2min)

Trial 4: __________kg (2min)

Trial 5: __________kg

Actual 1RM = ___________kg

NOTES:
______________________________________________________________________________
_______________________________________________________________________________

b. 1 RM single Leg Extension: (Alternate legs)
Back Rest: ____________________

Leg Rest: ____________________

Lifting Arm (Knees at 90⁰): _________________
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RIGHT LEG

LEFT LEG

Warm-up: 6 x 60% 1RM = ________kg (2min) Warm-up: 6 x 60% 1RM = ________kg (2min)
3 x 80% 1RM = ________kg (2min)

3 x 80% 1RM = ________kg (2min)

1RM Attempts: Trial 1: __________kg (2min) 1RM Attempts: Trial 1: __________kg (2min)
Trial 2: __________kg (2min)

Trial 2: __________kg (2min)

Trial 3: __________kg (2min)

Trial 3: __________kg (2min)

Trial 4: __________kg (2min)

Trial 4: __________kg (2min)

Trial 5: __________kg

Trial 5: __________kg

Actual 1RM = ___________kg

Actual 1RM = __________kg

NOTES:
______________________________________________________________________________
_______________________________________________________________________________
c. Hand Grip Dynamometer: (Alternate hands – 20-30 sec rest between trails)
RIGHT HAND

LEFT HAND

Trial 1: _________kg

Trial 1: _________kg

Trial 2: _________kg

Trial 2: _________kg

Trial 3: _________kg

Trial 3: _________kg

Mean of three : ___________kg

Mean of three: ___________kg

11. Questionnaires: (n/a for familiarization)
Completed all questions
12. Collect/Give out:
Familiarization
Give out:
 Questionnaires
 ActiGraph Monitor
 Explain ActiGraph Instructions

Baseline
Collect:
 ActiGraph Monitor
 Questionnaires

NOTES:
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
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Appendix S – Co-author declarations

Signed declarations from all co-authors of papers to confirm that I, Christelle
Schofield, contributed as significant manuscript writer and was responsible for all
data acquisition, as well as the majority of data analysis and interpretation.
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To whom it may concern
I, Christelle Schofield, confirm that, with reference to the papers titled:
1. “A Physiological Profile of Ovarian Cancer Survivors to Inform Tailored Exercise
Interventions and the Development of Exercise Oncology Guidelines” (Schofield C, Newton
RU, Galvão DA et al. Int J Gynecol Cancer. 2017; 27: 1560-1567).
2. “Activity behaviors and physiological characteristics of women with advanced-stage ovarian
cancer: a comprehensive cross-sectional investigation” (Schofield C, Newton RU, Galvão
DA et al. Int J Gynecol Cancer. Under review).
3. “Associations of objective activity behaviors and physiological characteristics with healthrelated quality of life and pelvic floor dysfunction in advanced-stage ovarian cancer
survivors” (Schofield C, Newton RU, Galvão DA et al. Prepared for submission).
I contributed as significant manuscript writer and was responsible for all data acquisition, as well as
the majority of data analysis and interpretation.
Signature: ______

__

I, as Co-Author, endorse that this level of contribution by the Candidate indicated above is
appropriate.
Dr. Paul A. Cohen, MD

Signature:

Date: 21.09.2017

Director Gynaecological Cancer Research Group, St John of God Hospital, Subiaco, Australia
Clinical Senior Lecturer, Department of Obstetrics and Gynaecology, School of Medicine,
University of Western Australia, Australia
Adjunct Professor, Institute for Health Research, University of Notre Dame Australia, Fremantle,
Australia
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To whom it may concern
I, Christelle Schofield, confirm that, with reference to the papers titled:

1.

“Activity behaviors and physiological characteristics of women with advanced-stage
ovarian cancer: a comprehensive cross-sectional investigation” (Schofield C, Newton
RU, Galvão DA et al. Int J Gynecol Cancer. Under review).

2. “Associations of objective activity behaviors and physiological characteristics with
health-related quality of life and pelvic floor dysfunction in advanced-stage ovarian
cancer survivors” (Schofield C, Newton RU, Galvão DA et al. Prepared for
submission).

I contributed as significant manuscript writer and was responsible for all data acquisition, as
well as the majority of data analysis and interpretation.

Signature:

I, as Co-Author, endorse that this level of contribution by the Candidate indicated above is
appropriate.
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